


Review

V γ 9V δ 2 T Cells: Can We Re-Purpose a Potent Anti-Infection Mechanism for Cancer Therapy?

Klaus-Peter Künkele ¹, Daniela Wesch ², Hans-Heinrich Oberg ², Martin Aichinger ¹, Verena Supper ¹  and Christoph Baumann ^{1,*}

¹ Boehringer Ingelheim RCV GmbH & Co KG, 1121 Vienna, Austria;

klaus-peter.kuenkele@boehringer-ingelheim.com (K.-P.K.);

Martin.Aichinger@boehringer-ingelheim.com (M.A.); Verena.Supper@boehringer-ingelheim.com (V.S.)

² Institute of Immunology, University Hospital Schleswig-Holstein, Christian-Albrechts University of Kiel, 24105 Kiel, Germany; daniela.wesch@uksh.de (D.W.); Hans-Heinrich.Oberg@uksh.de (H.-H.O.)

* Correspondence: christoph.baumann@boehringer-ingelheim.com; Tel.: +431-80105-6298

Received: 10 March 2020; Accepted: 28 March 2020; Published: 30 March 2020



Abstract: Cancer therapies based on in vivo stimulation, or on adoptive T cell transfer of V γ 9V δ 2 T cells, have been tested in the past decades but have failed to provide consistent clinical efficacy. New, promising concepts such as $\gamma\delta$ Chimeric Antigen Receptor (CAR) -T cells and $\gamma\delta$ T-cell engagers are currently under preclinical evaluation. Since the impact of factors, such as the relatively low abundance of $\gamma\delta$ T cells within tumor tissue is still under investigation, it remains to be shown whether these effector T cells can provide significant efficacy against solid tumors. Here, we highlight key learnings from the natural role of V γ 9V δ 2 T cells in the elimination of host cells bearing intracellular bacterial agents and we translate these into the setting of tumor therapy. We discuss the availability and relevance of preclinical models as well as currently available tools and knowledge from a drug development perspective. Finally, we compare advantages and disadvantages of existing therapeutic concepts and propose a role for V γ 9V δ 2 T cells in immune-oncology next to Cluster of Differentiation (CD) 3 activating therapies.

Keywords: V γ 9V δ 2 T cells; gamma delta T cells; cancer; infection; BTN3A; phosphorylated antigens; drug development; immuno-oncology

1. From Coley's Toxin to Pattern Recognition Receptors

Famous first steps in immuno-oncology were undertaken by William Coley, who attempted to treat cancer patients by administration of *Streptococcus pyogenes* and *Serratia marcescens*, later described as Coley's toxin [1]. Even though clinical statistics were not performed at today's scale, Coley left an amazing amount of data to suggest that although this treatment resulted in severe toxicity, cancer could be treated and even cured by bacterial infection. Although subsequent therapeutic discoveries have led to the emergence of alternative approaches to treat cancer, including radiotherapy, chemotherapy and targeted therapies [2], bacterial treatment has been further evaluated in the clinic. Bacille Calmette-Guerin (BCG) is a Food and Drug Administration (FDA)-approved live attenuated preparation of *Mycobacterium bovis* (TICE®, Organon Teknika Corp. or PACIS®, BioChemPharma) and currently used as a standard immunotherapy for the treatment of bladder cancer [3].

Research of the past decades has drawn a map of a highly diversified and sensitive alarm system that has evolved to detect non-self structures of pathogenic intruders or molecular indicators of damaged cells. Pioneering work by Charles Janeway and Ruslan Medzhitov predicted and subsequently identified the first pathogen pattern recognition receptors and highlighted the importance of the innate immune system in the overall immune response [4]. The innate immune system recognizes

pathogen-associated molecular patterns (PAMPs) or endogenous damage-associated molecular patterns (DAMPs), e.g., derived from essential bacterial functional or structural components, such as RNA or cell wall lipopolysaccharide (LPS) [5]. In the 21st century, the responsible mediators and mechanisms of the anti-tumor activity of Coley's toxin were identified: bacterial DNA and LPS stimulate Toll-Like Receptor (TLR) 9 and TLR4 signaling on a variety of immune cells, including Natural Killer (NK) cells and T cells, thereby enhancing their anti-tumor activity [6–8]. Additional studies have led to pathogen sensors being exploited therapeutically as drug targets to trigger a pro-inflammatory immune response [9,10]. Drug candidates acting as agonists of TLRs, of nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), or of stimulator of interferon genes (STING) entered the clinics with the aim to increase immune cell activation, infiltration and anti-tumor responses [11].

2. BTN3A1 is a PAMP Receptor

Butyrophilin 3 family member (BTN3) A1 is a transmembrane receptor that harbors two extracellular Immunoglobulin (Ig) -like domains and an intracellular B30.2 domain. The intracellular domain interacts directly with the bacterial metabolite (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) [12–14]. HMBPP is an essential intermediate product of the prokaryotic non-mevalonate/ 2-C-methyl-D-erythritol 4-phosphate/1-deoxy-D-xylulose 5-phosphate (MEP) pathway for isoprenoid synthesis, and is not generated by the mevalonate pathway, the human equivalent. BTN3A1 is exquisitely tuned to recognize this pathogen-derived molecule comparable to how TLRs recognize conserved pathogen structures, such as LPS or DNA [15–17]. The most intriguing difference, however, is the inside-out mode of action, where BTN3A1 senses its ligand in the cytosol and translates the signal to the cell surface [14] (Figure 1). Sophisticated structure based modeling and molecular data has led to the proposal that binding of HMBPP to the cytosolic B30.2 domain of BTN3A1 transmits this signal to the outside of the cell as a combination of a conformational change and receptor clustering [18–20]. Although an additional HMBPP binding site in the extracellular part of BTN3A1 has been proposed [21], the key role of intracellular HMBPP is further supported by the finding that extracellular HMBPP is degraded by the ecto-ATPase CD39 [22], preventing V γ 9V δ 2 T cell activation in an in vitro setting.

The functional consequence of a BTN3A1 infection alarm is the activation of V γ 9V δ 2 T cells. The detailed interface, and interactions of infected cells and the T Cell Receptor (TCR) on V γ 9V δ 2 T cells, have not been solved and remain one of the currently hot topics in the field. Recently, the discovery that the related butyrophilin, BTN2A1, is an essential co-factor for the interaction of BTN3A1 with the V γ 9 TCR chain (Figure 1) has added further details to our current picture of the molecular synapse. BTN2A1 thus might represent the long-sought factor X on human chromosome 6 whose absence in the mouse prevented the activation of transfected, human BTN3A by phosphoantigens in the murine system [23–25].

Even though the variable diversity joining (VDJ) recombination that generates the gammadelta ($\gamma\delta$) TCR can create an even higher degree of diversity than that observed with the $\alpha\beta$ TCR, V γ 9V δ 2 T cells respond to defined phosphorylated antigens which clearly does not require such a diversity [26]. Recent work has identified a conserved, germline-encoded region within the TCR variable region called hypervariable region 4 (HV4), which interacts with Butyrophilin family proteins and acts as a TCR intrinsic signal receiver. Therefore, it appears that the $\gamma\delta$ TCR is able to recognize two different signals [27]: an innate (pathogen derived) signal and an adaptive signal, which has not been identified yet, but which requires TCR diversity.




Figure 1. Butyrophilin 3 family member A1 (BTN3A1) is a pathogen-associated molecular pattern (PAMP) receptor. HMBPP from metabolically active bacteria, leaks into the cytoplasm where it is detected by the intracellular B30.2 domain of BTN3A1, triggering a conformational change within the protein. Thereby, the intracellular infection signal is transmitted through the plasma membrane to the surface, where BTN3A1 is constitutively associated with the Butyrophilin family member BTN2A1. Together they form an immunological synapse in which BTN2A1 interacts with the V γ 9 chain of the V γ 9V δ 2 TCR.

3. V γ 9V δ 2 T Cells in Infection

While $\gamma\delta$ T cells comprise 1%–10% of human Peripheral Blood Mononuclear Cells (PBMCs), V γ 9V δ 2 T cells are the major subset of $\gamma\delta$ T cells in peripheral blood, and make about 60%–95% [28]. In support of the proposed mode of action of phosphoantigen response, V γ 9V δ 2 T cells have been associated with the host defense to infectious diseases caused by intracellular pathogens, such as malaria [29], visceral leishmaniasis [30], listeriosis [31], tularemia [32] and tuberculosis [33,34]. All these pathogens share a common feature of using the non-mevalonate pathway for isoprenoid synthesis. Stimulation of human PBMCs with *Mycobacterium tuberculosis* (*M. tb.*) preparations [35] and infection of monocytes by *M. tb.* or *Salmonella*, demonstrated that pathogen infection and phosphorylated antigens can activate and trigger expansion of V γ 9V δ 2 T cells [36]. Furthermore, strong V γ 9V δ 2 T cell responses against *M. tb.* and *Listeria monocytogenes* infected host cells were demonstrated in in vivo infection models in macaques [37,38].

4. V γ 9V δ 2 T Cells in Cancer

Bioinformatic analyses of large meta-genomic datasets determined the relative abundance of V γ 9V δ 2 T cells within tumors and correlated this with patient outcome. Tumor-infiltrating $\gamma\delta$ T lymphocytes ($\gamma\delta$ TILs) were found in all tumor entities, albeit at low numbers. Importantly, a correlation

between relative abundance of $\gamma\delta$ TILs and favorable response to immune checkpoint therapy in a variety of cancers was demonstrated [39,40].

Transformation can lead to differential expression or re-location of molecular signals to the surface of cancer cells and entail recognition by the immune system. V γ 9V δ 2 T cells have been shown to be able to recognize these markers of stress, including TCR ligands F1-ATPase in complex with apolipoprotein A-I, or hMSH2, a DNA mismatch repair protein [41,42].

It has been speculated that dysregulation of the mevalonate pathway during tumorigenesis is able to generate high intracellular levels of isopentenyl pyrophosphate (IPP) and that V γ 9V δ 2 T cells can sense this increase via signals to the BTN3A receptor [43]. IPP is the human metabolite most structurally homologous to bacterial HMBPP and has been shown to be able to trigger V γ 9V δ 2 T-cell activation and proliferation in an in vitro setting. It must be noted these effects required considerably higher concentrations (10000- to 30000-fold) of externally added IPP compared to the bacterial metabolite [44]. Although the intracellular IPP levels in cancer cells could be accumulated by up to 960-fold via downstream inhibition of farnesyl-diphosphate synthetase (FDPS) using aminobisphosphonates [45,46], without this intervention, only minimal cell killing was observed when V γ 9V δ 2 T cells were cultivated with a panel of tumor cells [47–50]. This indicates that natural IPP levels in most transformed cells may not be sufficient for activation of V γ 9V δ 2 T cells.

Importantly, in the presence of soluble BTN3A1 agonists, V γ 9V δ 2 T cells have been shown to be highly effective in cancer cell killing in co-culture experiments at various target: effector ratios. This requires BTN3A1 activation on tumor cells as pre-incubation of a BTN3A1 agonist with the effector T cells before addition to the target cells does not lead to tumor cell lysis, even at high T-effector: cancer cell ratios [13]. The data are further supported by another study showing that infected cells are much better activators of V γ 9V δ 2 T cell activity than heat-killed bacteria themselves [36]. This finding implies that an efficient target elimination signal must be traceable back to the infected/target cell. Indeed, V γ 9V δ 2 T cells build a synapse with the signal submitting target cell, which allows selective elimination of cells that harbor intracellular infection.

Recent advances in the sensitive detection of pathogens revealed that tumors harbor a diverse set of bacteria, viruses and fungi [51,52], a community, which, in analogy to the “microbiome” in the gut, has been labeled the “oncobiome” [53]. Sequencing of bacterial 16S RNA as a species-specific genetic fingerprint identified several hundred different bacterial species in each tumor [54]. There is increasing evidence that the oncobiome contains genes for the production and delivery of genotoxic molecules, of toxins altering the signaling pathways of the host cells, of enzymes metabolizing cancer therapeutics and of factors suppressing immune cell functions [55–59]. While the oncobiome, thus, has the means to drive tumorigenesis, progression, resistance and immune escape, the tumor cells on the other hand provide intracellular niches for bacterial growth. Tumor cells bearing activating mutations in the KRAS oncogene or phenotypically similar mutations show extensive macropinocytosis facilitating the transport of both, bacteria and nutrients, into the same intracellular compartments [54]. In contrast to extracellular bacteria that benefit from the death of tumor cells and the accompanying release of nutrients, e.g., in necrotic tumor regions, intracellular bacteria benefit from the survival of their proliferating tumor cell host. The host cell provides unlimited space and nutrition as well as protection against most immune cells—except V γ 9V δ 2 T cells, which are especially equipped to detect metabolically active bacteria occupying intracellular niches. It is, thus, tempting to speculate that HMBPP produced by bacteria of the oncobiome might be an important factor for the enrichment of V γ 9V δ 2 T cells in neoplastic regions and their positive impact on patient outcome.

5. Plasticity of V γ 9V δ 2 T Cells

5.1. Cytotoxicity

The strong cytolytic activity of V γ 9V δ 2 T cells is not only directed towards cells with intracellular bacterial infection but also against the pathogen itself. Effector functions of $\gamma\delta$ T-cells includes induction

of CD95/ CD95-Ligand and Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL)/ TRAIL-Receptor (R) signaling to induce target cell apoptosis [60,61] and secretion of cytotoxic substances, including granzyme, granulysin and perforins, which are active against both the infected host cell as well as the pathogen [62–64]. Hence, the recognition of BTN3A activated by phosphoantigens can elicit cytotoxic effector functions of V γ 9V δ 2 T cells. In addition, stimulation through phosphoantigens and Interleukin (IL)-2 can upregulate the expression of Fc γ RIII (CD16) in circulating V δ 2 T cells [65], which when combined with therapeutic antibodies such as Rituximab or Obinutuzumab can enhance the antibody dependent cellular cytotoxicity (ADCC) of V γ 9V δ 2 T cells and enhance their lytic activity on cancer cells, especially in hematological indications [66,67] and Neuroblastoma [68]. In another study, activated V γ 9V δ 2 T cells bound to Trastuzumab-treated breast cancer cells via CD16 and thereby exerted ADCC. The adoptive transfer of these activated V γ 9V δ 2 T cells together with Trastuzumab reduced growth of breast cancer tumors grafted into immune-compromised mice [69]. A very promising strategy to overcome certain limitations of Trastuzumab may be the use of the bispecific antibody [(HER2) $_2$ xCD16] which re-directs CD16 $^+$ $\gamma\delta$ T cells to the tumor-associated cell surface antigen human epidermal growth factor receptor (HER)-2. The enhanced efficacy of [(HER2) $_2$ xCD16] can be explained by an increased degranulation and an enhanced cytotoxic activity against tumor cells which are resistant to CD95- or TRAIL-R induced cell death [70]. In sum, $\gamma\delta$ T-cell cytotoxicity against tumor cells can be induced by different activation pathways and some of them may be more susceptible to immune suppressive mechanisms than others, depending on the specificity of the triggering non-self signal. Additionally, activation of V γ 9V δ 2 T cells induces a $\gamma\delta$ T- antigen presenting cell (APC) phenotype and, thereby, the possibility to take up antigens including tumor antigens and to present them to $\alpha\beta$ T cells [71,72].

5.2. Antigen Presentation

Recognition of tumor neo-antigens by T cells is fundamental to cancer immunotherapy and, hence, tremendous efforts are being undertaken to promote antigen presentation within the tumor [73]. Professional antigen presenting cells, in particular dendritic cells, are in the spotlight due to their ability to enhance local tumor recognition [74]. Strikingly, V γ 9V δ 2 T cells have been shown to be as potent as dendritic cells in their ability to present antigen to CD4 $^+$ and to cross present to CD8 $^+$ T cells [72]. Once they become activated, they either take up soluble antigen, as shown for the tumor antigen peptide Mart-1, or they phagocytose opsonized target cells [71,75]. After their activation, co-stimulatory molecules CD80 and CD86 as well as Major Histocompatibility Complex I (MHC-I) and MHC-II molecules are up-regulated on the surface together with the chemokine receptor CCR7, which directs the $\gamma\delta$ T cells to the lymph nodes (LN); thus, increasing the likelihood that they interact with and activate CD4 $^+$ and CD8 $^+$ $\alpha\beta$ T cells [72].

In addition to their innate function, revealed by recognition and phagocytosis of pathogens and cross-presentation of antigens, $\gamma\delta$ T cells rapidly produce cytokines and chemokines after activation, induce the maturation of dendritic cells, and have the capacity to kill various bacteria-infected Antigen Presenting Cells (APCs) and tumor cells in a HLA-non-restricted manner. Taken together, this illustrates their function as initiators of full-blown anti-infection adaptive immune responses as unique bridging cells between innate and adaptive immunity.

5.3. Clonal Expansion

Even though V γ 9V δ 2 T cells constitute the largest population of $\gamma\delta$ T cells in the peripheral blood, their abundance within CD3 $^+$ T cells in healthy donors is relatively low. In an infection setting, however, V γ 9V δ 2 T cells undergo massive expansion [76–78]. This has been best exemplified in Rhesus macaque models of *M. tb.* infection where initial pathogen challenge induced a strong V γ 9V δ 2 T cell-expansion over three weeks, followed by up to 1000x expansion of V γ 9V δ 2 memory T cells upon re-call infection with BCG [38]. In fact, in the presence of infection, V γ 9V δ 2 T cells can rapidly increase to represent up to 60% of peripheral T cells [79]. Most strikingly in this context is their ability to home back to the

diseased and infected tissue after expansion. In *M. tb.* models, expanded V γ 9V δ 2 T cells exhibited trans-endothelial migration, interstitial localization and granuloma infiltration [80]. Similarly, V γ 9V δ 2 T cells increased drastically in numbers in non-human primate models of *Listeria monocytogenes* infection, expressed an effector memory phenotype and produced granzymes, perforin and pro-inflammatory cytokines [37]. Hence, the ability of these cells to rapidly expand to high numbers could be potentially exploited also in a cancer setting once appropriately stimulated.

5.4. Suppressor Functionality of $\gamma\delta$ T Cells

Similar to the functional diversification observed within CD4⁺ T cells, in vitro differentiation studies have brought forward the hypothesis that both tumor promoting and pro-inflammatory, anti-infective populations of $\gamma\delta$ T cells exist [81]. On the one hand, activation of T cells by antigens in vitro results in secretion of cytokines, especially Tumor Necrosis Factor (TNF)- α and Interferon (IFN)- γ , and initiates pro-inflammatory, anti-infection responses [37]. On the other hand, V δ 2 T cells activated and expanded in vitro using CD28 agonistic antibodies, or by co-cultivation with IL-12 expressing dendritic cells, have been shown to exert suppressive functions on CD4⁺ T cells [82,83]. In fact, regulatory $\gamma\delta$ T cells have been described that exhibit classical suppressive features, such as up-regulation of Programmed Death-Ligand (PD-L) 1 and secretion of Transforming Growth Factor (TGF)- β [84,85]. Hence, there seems sufficient evidence that inhibitory phenotypes of $\gamma\delta$ T cells, including the V γ 9V δ 2 subpopulation, can be differentiated and described in vitro and ex vivo.

In primary tumors from patients with colorectal cancer, the bacterial induced activation of dendritic cells led to the polarization of $\gamma\delta$ T cells into IL-17 producing $\gamma\delta$ T cells, which recruited and induced the proliferation and survival of immunosuppressive polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) [86]. Of note, $\gamma\delta$ T cells were detected with a pan TCR $\gamma\delta$ antibody not permitting discrimination between $\gamma\delta$ T cell subpopulations.

Furthermore, the accumulation of V δ 1 Tregs in mammary tumors was correlated with poor survival [87] and in yet another study tumor infiltrating, tumor promoting $\gamma\delta$ T17 cells have also been identified as V δ 1 T cells [86]. Interestingly, the clinical outcome of adoptive transfer of V γ 9V δ 2 T cells in patients with terminal breast cancer or hormone refractory prostate cancer correlated significantly and positively with sustained levels of V γ 9V δ 2 T cells in the peripheral blood [88,89]. Therefore, while it has been sufficiently elaborated that V γ 9V δ 2 T cells can potentially occur with suppressive features, their occurrence as such in primary tumors together with their implication for favorable outcome, might be different from other $\gamma\delta$ T cell subpopulations and requires further investigation.

Despite the evidence of discrete populations of $\gamma\delta$ T cells with opposite activities, a series of arguments speak in favor of harnessing the activity of V γ 9V δ 2 T cells to treat cancer. TGF- β secretion by V γ 9V δ 2 T cells is much lower than V δ 1 or CD4⁺ T cells and some reports suggest that TGF- β can actually enhance the cytotoxic activity of V δ 2 T cells [84]. Combination with TLR2, TLR3, TLR7 or TLR8 agonists abrogates the $\gamma\delta$ T cells inhibitory effects in vitro and results in polarization towards a potent Th1 response [90–93]. Interestingly, activation of V γ 9V δ 2 T cells via phosphorylated antigens in monkey *M. tb.* in vivo models diminished IL-2 induced activation of CD4⁺ Tregs [94], suggesting BTN3A activation triggers predominantly an anti-suppressive effect. It is apparent that further studies are required to better understand the characteristics of $\gamma\delta$ T cells in tumors and, especially, how their activation can be best exploited for cancer therapy [95,96].

6. Targeting V γ 9V δ 2 T Cells in Cancer Therapy

6.1. Adoptive T Cell-Transfer and In Vivo Stimulation

The capability of V γ 9V δ 2 T cells to undergo massive clonal expansion in infection settings is being exploited ex vivo using direct or indirect BTN3A agonists BrHPP or amino-bisphosphonates (such as zoledronic acid) in combination with IL-2. Many in vitro expansion protocols for $\gamma\delta$ T cells have been established, opening the door for large-scale experiments, pre-clinical models and adoptive

transfer studies [67,97] (Table 1). In the context of cancer therapy, it is now possible to highly enrich autologous cells by ex vivo expansion and re-infuse them into a cancer patient. This leads to elevated amounts of $\gamma\delta$ T effector cells, which, otherwise, are not found in comparable abundance in cancer patients, especially when compared to the high numbers of $CD8^+$ $TCR\alpha\beta^+$ T-effector cells in the peripheral blood [64,98]. Subsequently, ex vivo expanded $V\gamma9V\delta2$ T cells have been repeatedly used in early clinical Phase I adoptive transfer studies over the past 15 years (Table 1). The tolerability of adoptive transfer and low dose IL-2 was overall quite well and observed toxicities derived mainly from additional combination partners [99]. Even though the patient numbers are too low to draw significant conclusions on the efficacy side, it is interesting to note that in treatment schedules where $V\gamma9V\delta2$ T cells were expanded ex vivo with the direct BTN3A ligand 2M3B1-PP, or where Zoledronate was co-administered in addition to $V\gamma9V\delta2$ T cells, some partial or even complete remissions were observed [100–102]. Interestingly, expansion and survival of adoptively transferred $V\gamma9V\delta2$ T cells in Colorectal Cancer (CRC) patients without co-infusion of supporting cytokines was working well and suggested promoting function of endogenous IL-2 or IL-15 [103]. Furthermore, in a pilot study with four patients who had different hematological malignancies, three complete remissions were achieved when half matched $V\gamma9V\delta2$ T cells from family donors were transferred. Importantly, no graft versus host disease (GVHD) was observed [104].

Table 1. Completed Phase I clinical trials with adoptive transfer of ex vivo expanded, autologous $V\gamma9V\delta2$ T cells. RCC: Renal Cell Carcinoma. MM: Multiple Myeloma. NSCLC: Non-small cell lung cancer. HCC: Hepatocellular Carcinoma. CRC: Colorectal Carcinoma. PR: Partial Response. SD: Stable Disease. CR: Complete Response. ¹ Bromohydrin Pyrophosphate (BrHPP). ² Natural Killer (NK) cells. ³ Cytokine Induced Killer Cells (CIK)

Reference	Indication	Treatment	Ex Vivo Expansion Stimulus	n	Response
[100]	RCC	$\gamma\delta$ T cells	2M3B1-PP + IL-2 Teceleukin	7	3 PR
[105]	RCC	Innacell $\gamma\delta$ T cells + IL-2	BrHPP ¹ + IL-2 Proleukin	10	6 SD
[106]	MM	$\gamma\delta$ T cells	Zoledronate + IL-2	6	0
[107]	NSCLC	$\gamma\delta$ T cells	Zoledronate + IL-2	10	3 SD
[101]	RCC	$\gamma\delta$ T cells + Zoledronate + IL-2	2M3B1-PP	11	1 CR 5 SD
[108]	Diverse solid tumors	$\gamma\delta$ T cells + Zoledronate	Zoledronate + IL-2	18	3 SD
[109]	Diverse solid tumors	$\gamma\delta$ T cells + combinations	Zoledronate + IL-2	25	3 PR
[110]	NSCLC	$\gamma\delta$ T cells	Zoledronate + IL-2	15	6 SD
[111]	HCC	Radiofrequency ablation + cytokines	NK ² , CIK ³ , $\gamma\delta$ T stimuli	30	
[103]	CRC	$\gamma\delta$ T cells	Zoledronate + IL-2	6	
[102]	Gastric cancer	$\gamma\delta$ T cells + Zoledronate	Zoledronate + IL-2	7	1 PR, 1 CR
[99]	Pancreatic Cancer	$\gamma\delta$ T cells + Gemcitabine	Zoledronate + IL-2	28	
[104]	Hematological	$\gamma\delta$ T cells (family donor) Zoledronate + IL-2	CD4 ⁺ and CD8 ⁺ T cell depleted PBMCs	4	3 CR

Alternatively, clinical trials have also evaluated expansion of $V\gamma9V\delta2$ T cells in the patient by administration of amino-bisphosphonates plus low dose IL-2. Reports from multiple clinical studies suggest that these approaches are well tolerated and, importantly, the clinical outcome was promising: in 3 out of 10 terminal breast cancer patients, two stable disease and one partial response have been observed [88] (Table 2). Despite the overall low patient numbers, in several studies a correlation between efficacy and the functionality and peripheral blood levels of $V\gamma9V\delta2$ T cells was proposed [88,89,112]. Importantly, the peripheral blood numbers of $V\gamma9V\delta2$ T cells could be increased, when IL-2 was co-administered to the patient [89]. Yet, repeated administration of IL-2 and Zoledronate seemingly reduced the effector cell levels suggestive of induction of anergy or activation induced cell death (AICD) [113]. Taken together, despite some signs of efficacy, the general patient response has been below expectations so far [114].

Table 2. Completed Phase I clinical trials with in vivo stimulation of gamma delta T cells. RCC: renal cell carcinoma, CRC: colorectal cancer. NHL: Non Hodgkins Lymphoma, MM: Multiple myeloma. OR: Overall Response. SD: stable disease. PR: partial response. AML: acute myeloid leukemia. Peripheral Blood Lymphocytes (PBL)

Reference	Indication	Treatment	n=	Response	Response Biomarker
[112]	Hematological (NHL + MM)	Pamidronate + IL-2	19	3 SDs	V γ 9V δ 2 PBL
[89]	Prostate Cancer	Zoledronate/Zoledronate + IL-2	18	1 SD, 1 PR 4 SD, 2 PR	TRAIL, V γ 9V δ 2 PBL
[115]	RCC, CRC, Breast Cancer	BrHPP + IL-2	28		
[88]	Breast Cancer	Zoledronate + IL-2	10	2 SD, 1 PR	V γ 9V δ 2 PBL
[113]	Metastatic RCC	Zoledronate + IL-2	12		V γ 9V δ 2 PBL
[116]	RCC, melanoma, AML	Zoledronate + IL-2	21	0 in solid tumors, 2 PR in AML	IFN- γ and in vivo expansion
[117]	Refractory neuroblastoma	Zoledronate + IL-2	4	1 SD	V γ 9V δ 2 PBL

6.2. Chimeric Antigen Receptor T Cells (CAR-Ts)

The remarkable clinical response observed in patients with B-cell malignancies has led to FDA-approval of CD8⁺ CAR-T cells [118]. In CAR-T cells, a recombinant, chimeric $\alpha\beta$ TCR molecule is introduced into the patient's own CD8⁺ T cells to guide antigen specific tumor selectivity and to mimic an already expanded effector T-cell population.

One major limitation of this approach is the necessity to use the patient's own T-cells, a personalized therapy that prevents the usage of allogeneic CAR-T cells as an off-the-shelf drug. This poses logistical hurdles to provide clinical-grade CD8⁺ CAR-T generation at a global level. Companies, such as Collectis or Celyad, have addressed this issue by developing technologies to knock out the endogenous $\alpha\beta$ TCR, thereby achieving allo-tolerability. Alternatively, CAR-T therapies are under development using $\gamma\delta$ T cells, which circumvent this issue by recognizing innate antigens in a MHC-independent manner [119]. Gadeta is testing the safety of TEG001 in patients with relapsed/refractory acute myeloid leukemia (AML), myelodysplastic syndrome or multiple myeloma. TEG001 consists of autologous $\alpha\beta$ T cells genetically transduced with a $\gamma\delta$ TCR. The $\gamma\delta$ TCR is added to allow recognition of malignant cells. The extensive investment in this area (e.g., in companies such as Puretech and Medinet) demonstrates the excitement to identify approaches to generate new recombinant CAR-T modalities which will reduce the requirement for autologous cells, add $\gamma\delta$ T cell effector functions or bring alternative methods of tumor cell recognition. It is apparent, however, that therapeutic success is highly dependent on the tumor directed cytotoxic activity of T effector cells and it remains to be seen how strongly this impacts the clinical success of different $\gamma\delta$ CAR-T approaches.

6.3. BTN3A Agonistic Antibody

One of the most important tools generated in BTN3A research is the 20.1 agonistic antibody, which is now moving towards clinical development. This antibody originally helped to elucidate the BTN3A mode of action, effectively activating the receptor without the requirement for intracellular HMBPP or equivalent ligand binding [120,121]. Preclinical efficacy has been shown in $\gamma\delta$ T cell adoptive transfer models of AML [122] and subsequently, Imcheck Therapeutics has introduced ImCheck Therapeutics (ICT)-01, a humanized BTN3A agonistic antibody, in Phase I trials in patients with hematological malignancies.

6.4. T Cell Engager Approaches: $\gamma\delta$ T Cell Engagers ($\gamma\delta$ TcE)

Recognition of the tremendous potential of tumor antigen targeted activation of CD3⁺ T cells [123] has driven drug development in this area. Activity observed in pre-clinical studies [124] and potent efficacy in clinical trials, including long-term remissions, has led to the approval of blinatumomab ([CD3xCD19] BiTE) for the treatment of acute lymphoblastic leukemia (ALL) patients [125–127]. Clinical development of TcEs in solid tumors has lagged behind hematological malignancies with most data being around Amgen's solitomab, an EpCAM⁺ CD3 BiTE. Clinical development was discontinued following evidence of serious toxicities [128]. Learnings from this approach have led to the development of AMG757, a DLL3-CD3 BiTE molecule in Phase I clinical testing, where utilization of a more tumor selective anchor protein, DLL3, raises hopes for reduced toxicity (<https://clinicaltrials.gov/ct2/show/NCT03319940>). The suppressive milieu in solid tumors may also limit the clinical efficacy of TcE approaches [98,129]. Accordingly, combination treatments are being tested pre-clinically and in the clinics to tip the balance of activation from the suppressors to tumor cell killers [130,131].

Even though there are some differences in the receptor architecture, the $\gamma\delta$ TCR ensemble is structurally similar to the $\alpha\beta$ TCR, carrying a CD3 subunit that can potentially be activated by an agonistic antibody [132]. While CD3 agonistic antibodies can readily activate and expand V γ 9V δ 2 T cells in the absence of IL-2, activation via CD3 in the presence of IL-2 induced growth arrest and apoptosis. Notably, the same cytokine is commonly used to boost clonal expansion of V γ 9V δ 2 T cells in the presence of phosphoantigens [133]. Akin to CD3 T-cell engagers, bispecific antibodies such as the Tribodies [(HER2)₂xV γ 9] or [(HER2)₂xCD16] demonstrated that significant cytotoxicity can be achieved when target and effector $\gamma\delta$ T cells are linked [70,134]. LAVA therapeutics has developed this approach further, generating a pre-clinical pipeline of different tumor anchor binding molecules linked to $\gamma\delta$ TCR engaging antibodies. In contrast to $\gamma\delta$ CAR-Ts and adoptive transfer studies, $\gamma\delta$ T cell-engagers have to deal with the initially low effector cell numbers present in the system. On the other side, similar to the effector to target synapsis formation induced by CD3 T-cell engagers, they provide an alternative way of guiding $\gamma\delta$ T effector cells to their target cells to induce cytotoxic activity.

7. V γ 9V δ 2 T-Cell Functionalities in Tumor Targeting

Even though not all of the above-mentioned therapeutic approaches are primarily based on V γ 9V δ 2 T cells, some common features linked to successful anti-tumor therapy are nevertheless shared. First of all, it is important to have sufficient numbers of effector cells to eliminate a solid tumor, especially considering the relatively low relative number of T-effector cell to tumor cells in late stage cancer. Obviously, adoptive transfer of autologous or even “off the shelf” V γ 9V δ 2 T cells will provide T-effector cell numbers, which will match or top the levels reached in infection settings. It is however still an open question if their cytolytic activity could be triggered by the endogenous level of IPP in tumor cells or by the low number of intracellular bacteria present in a fraction of the tumor cells [55]. As discussed above, if a given therapy was equally effective in stimulating cell expansion as intracellular pathogenic intruder detection by BTN3A, it might be able to exploit the tremendous expansion potential of V γ 9V δ 2 T cells. It will be helpful to clarify whether numbers of peripheral blood and/or tumor V γ 9V δ 2 T cells correlate with treatment success, what the minimal requirement for eliciting a response would be, and if the immune response has to be boosted by the addition of cytokines, such as IL-2 or other immune stimuli.

It remains to be tested, which modality will be triggering which of the known V γ 9V δ 2 T-cell features (Figure 2). In addition to the direct cytotoxic activity, the concerted action of several effector functions, such as the ability to harness secretion of pro-inflammatory cytokines, antigen presentation or proliferation might contribute to the overall therapeutic outcome and long-term protection against the tumor.




Figure 2. Immune functions of Vγ9Vδ2 T cells. An infection signal derived from an infected cell and mediated via BTN3A will induce a variety of cellular functions as follows: (i) lysis of the infected cell by cytotoxic mediators, such as granzymes, perforins or via the FAS7-associated cell surface Antigen (Fas)/(CD95) and TRAIL-receptor induced cell death pathways; (ii) soluble material and opsonized, phagocytosed cellular material is digested and presented to TCR αβ⁺ CD4⁺ and CD8⁺ T cells; (iii) a clonal expansion up to 1000-fold increase after stimulation with their selective antigens; (iv) stimulated γδ T cells release many different cytokines and chemokines, most importantly the pro-inflammatory molecules TNF-α and IFN-γ.

8. Towards Precision Immune-Oncology

In contrast to hematological malignancies, solid tumors pose a greater problem in terms of immune biomarker determination. We still lack the detailed means to discriminate the immune cell subsets and their activation status in the tumor in a standardized fashion. However, recent efforts have come up with promising directions, such as the Immunogram [135], a collection of parameters describing the immune status, mutational burden, etc., of a tumor as an approach to identify tumors that would be responsive to immune-oncology therapies. Such an approach could be adapted to include T cell-subsets, such as Vγ9Vδ2 T cells, in the prediction of patient immune cell status and personalized therapy [136]. Indeed, Cibersort computational analyses have already shown that, with the right resolution, we might be able to discriminate and quantify immune cell subsets down to Vγ9Vδ2 T cells from sequencing data [39,40]. Other immuno-oncological (IO) biomarker approaches analyze tumor mutational burden or IFN-γ signatures and have been shown to have a high predictive value if used in combination [137]. In the end, the complexity of the immune system might require a comprehensive approach integrating multiple facets, including inflammation markers, epitope burden/neo-epitope occurrence, checkpoint receptor expression, suppressor cell populations, as well as T-cell-subset profiling to identify the right drug for the right patient [138].

Lessons from clinical trials might help to refine future patient selection biomarkers. Although Blinatumomab is considered the best therapeutic option for refractory ALL patients, it is important to note that 52% of treated patients show no response [139,140]. Biomarker analysis in a large sub-cohort of patients found the most significant biomarker correlating with patient response to be the number of CD4⁺ Tregs present in the peripheral blood (a cutoff of < 8.5% CD4⁺ Tregs in peripheral blood was able to identify 100% of responders and exclude 70% of non-responders) [141]. Subsequent ex vivo experiments with immune cell subsets purified from patient PBMCs demonstrated that lack of efficacy is caused by suppression of CD8⁺ T-cell activation. Indeed, the activation of CD3 on CD4⁺ Tregs by blinatumomab silenced the cytotoxicity of Cytotoxic T-Lymphocytes (CTL) [141]. Thus, as with other immune-oncology concepts, the success of CD3 activating antibody therapeutics relies heavily on the balance between suppressor cells and effector cells. Hence, in tumors where immune suppression does not allow for sufficient activation of effector T cells with a panCD3-activating compound, it might be more efficient to avoid further activating immune suppressive CD3 T cell subsets, but focus activation on smaller but specifically cytotoxic subsets.

9. Preclinical Modeling

Mouse models have been invaluable in making complex physiological processes experimentally accessible [142]. Despite a lack of conservation of some aspects of immune biology between mice and humans, much of our current understanding of health and disease stems from, arguably, extrapolating results obtained in preclinical models to human biology. One of the more challenging aspects in this context is the exploration of $\gamma\delta$ T cell function [143]. While the murine counterparts have been extensively studied in recent decades [144], strategies to study human cells in the mouse context remain experimentally more demanding. The reconstitution of immunocompromised murine hosts with selected cells of human origin, a process often referred to as “humanization”, is a widely used approach to study human cancer, human immune cells, but also many other human cell types under physiologic conditions [145].

Several studies, aimed at exploring the potential of V γ 9V δ 2 T cells as anti-cancer effectors (summarized in Table 3), have used similar strategies. The effect of adoptive transfer of in vitro expanded V γ 9V δ 2 T cells on the growth of established human tumors in immunocompromised mice (e.g., NSG, NOG, SCID, Foxn1^{nu/nu}) was evaluated. In most studies, phosphoantigen-mediated activation and supplementation with growth-promoting cytokines have been employed to expand V γ 9V δ 2 T cells from PBMCs prior to adoptive transfer. Only few studies, however, have addressed the fate of adoptively transferred V γ 9V δ 2 T cells in mice. Although tracing studies suggest in vivo cell survival for periods of at least one to two weeks upon adoptive transfer [146,147], the functional activity of V γ 9V δ 2 T cells re-isolated from tumor bearing mice had vanished over time [147]. Hence, the requirement for high numbers and repetitive administration of human $\gamma\delta$ T cells in these models may—at least in part—be ascribed to their limited persistence and functional activity in murine hosts [147]. Regardless, the sum of available data (Table 3) clearly demonstrate potent anti-tumor effector function of V γ 9V δ 2 T cells across indications and experimental setups [148].

Despite the variety of different cancer models and experimental approaches tested so far, it is apparent that repeated transfer of V γ 9V δ 2 T cells correlated with more pronounced tumor control. These conclusions are supported by an intracranial glioblastoma model [149], melanoma and pancreatic adenocarcinoma models [147], subcutaneous models of ovarian cancer [150], prostate cancer [151] and nasopharyngeal carcinoma [152].

The requirement for exogenous BTN3A ligands in V γ 9V δ 2 T cell mediated anti-tumor efficacy is less consistent. Although administration of bisphosphonates (e.g. zoledronate, alendronate or pamidronate) or 20.1 mAb [121] generally promoted V γ 9V δ 2 T cell mediated tumor killing, there appears to be some variability in the requirement for additional external stimuli. The majority of reports involving solid tumors suggest a stronger dependence on BTN3A agonism [50,147,149–151,153–155] than hematologic tumors [156–159].

From adoptive transfer studies in humans it has become apparent that V γ 9V δ 2 T cell mediated efficacy correlated with their proliferation, which was enhanced when IL-2 was administered [112]. Thus, while IL-2 is recognized as a crucial co-factor for V γ 9V δ 2 function and proliferation [160], the natural sources for IL-2 such as especially CD4⁺ Helper cells are absent in immunocompromised mice. Exogenous complementation of cytokine in murine models has, thus, been used in many experiments [134,147,161,162]. In contrast, studies that have not administered IL-2 in addition to the respective drug (Table 3) have also reported efficacy, suggesting that expanded and IL-2 pre-activated V γ 9V δ 2 T cells, which are repetitively administered, can be sufficiently active and viable in the mouse to mediate efficacy without cytokine addition.

It is important to stress that only a very limited spectrum of V γ 9V δ 2 T cell biology can be faithfully addressed in these preclinical mouse models. While direct target cell killing can be readily assessed, the absence of accessory cells precludes examination of cellular functions described in Figure 2, such as antigen cross-presentation or production of pro-inflammatory cytokines.

An appealing way to bring complexity to tumor models while even maintaining immune cell diversity in a completely human setting are patient-derived ex vivo co-culturing experiments. Tumors of cancer patients removed during surgery were dissected and singularized tumor tissues as described elsewhere [64]. In brief, primary tumor tissue derived tumor cells and tumor-associated cells can be co-cultured with autologous isolated tumor-infiltrating cells (TIL) or autologous or allogeneic PBMC. Hence, other than in the above-described in vivo adoptive T-cell transfer in mouse studies, here the complexity of the tumor intrinsic immune system is largely maintained in an autologous, human system, which reflects the composition and phenotype of the different cells within the tumor tissue. Ex vivo cultivation of the original mixture of tumor cells and TILs with or without the addition of autologous PBMCs allows the more closely monitoring of the cytokine- or cytotoxic mediator expression using multicolor flow cytometry [64,134]. The cytotoxic activity of effector cells within the tumor tissue can be analyzed by applying the tumor tissue to a Real Time Cell Analyzer (RTCA, X-Celligence, ACEA Biosciences, San Diego, CA, USA), which allows measurement over an extended time course as described elsewhere [166]. Moreover, the assay enables the assessment of immune cell numbers and activation states by flow cytometry at the beginning and end of the experiment and its modulation upon pharmacological intervention. In contrast to the limited immune biology reflected in the adoptive transfer mouse models (see above)—the RTCA technology allows studying efficacy, immune cell phenotypes and their cross-talk at a timely resolution in an autologous, patient derived tumor setting. Hence, this methodology can be of great use when trying to reduce the translational gap between preclinical and clinical research and development.

Table 3. Summary of dual xenograft in vivo mouse studies involving V γ 9V δ 2 T cells. (i.v.) intravenous; (i.p.) intraperitoneal; (s.c.) subcutaneous.

Reference	Number of Transferred Cells	Route	Cell Source	Administration	<i>In Vivo</i> BTN3A Activation	Exogenous Cytokine Administration	Tumor	Mouse Strains
[122]	3×10^7 V γ 9V δ 2	i.v.	PBMC	single	20.1 mAb	IL-15/IL-15ra (RLI)	Primary AML, U937	NSG
[161]	1×10^6 $\gamma\delta$ T cells	i.p.	$\gamma\delta$ TILs/TALs	single	none	IL-2	Daudi/SKOV3	BALB/c nude
[162]	2×10^7 V γ 9V δ 2	i.p.	PBMC	repetitive	zoledronate	IL-2	MM1 CML	SCID
[163]	2×10^7 $\gamma\delta$ T cells	i.v.	PBMC	repetitive	none	none	2LMP	SCID
[153]	5×10^6 V γ 9V δ 2	i.v.	PBMC	repetitive	zoledronate	no	SH-SY-5Y	BALB/c nude
[164]	5×10^6 $\gamma\delta$ T cells	s.c.	PBMC	single	none	no	NCI-H460	SCID
[154]	4×10^7 V γ 9V δ 2	i.v.	PBMC	single	alendronate	no	A375	SCID
[156]	4×10^7 V γ 9V δ 2	i.v.	PBMC	single	no	no	U937	NOG
[149]	1×10^7 V γ 9V δ 2	intracranial	PBMC	single and repetitive	zoledronate	none	U-87MG/orthotopic GBM	NSG
[147]	various	i.p.	PBMC	repetitive	alendronate	IL-2	MeWo PancTu1	SCID
[165]	2×10^6 V γ 9V δ 2	i.v.	PBMC	repetitive	none	IL-2	Autolog. melanoma	CB.17 SCID
[146]	1×10^7 V γ 9V δ 2	i.v.	PBMC	single	aledronate zoledronate	no	MDA-MB-231-hNIS.GFP	NSG
[157]	1×10^7 V γ 9V δ 2 enriched PBMCs	i.p.	PBMC	repetitive	none	no	Daudi	SCID
[150]	1×10^6 V γ 9V δ 2	i.v.	PBMC	single and repetitive	pamidronate	no	OVCAR-3	NSG
[134]	$1.5 - 3 \times 10^5$ V γ 9V δ 2	s.c.	PBMC	repetitive	Zoledronate [(Her2) $_2$ xV γ 9]	IL-2	PancTu-I (PDAC)	SCIDbeige
[155]	1×10^7 V γ 9V δ 2	i.p.	PBMC	single and repetitive	aledronate zoledronate	no	SKOV-3 IGROV	SCID
[151]	1×10^6 V γ 9V δ 2	i.v.	PBMC	single and repetitive	pamidronate	no	PC3	NSG
[158]	1×10^7 PBMC +/- V γ 9V δ 2	i.v.	PBMC	repetitive	pamidronate	no	EBV induced B cell lymphoma	Rag2-/- γ c -/-
[50]	1×10^7 V γ 9V δ 2	intravesicular	PBMC	single	zoledronate	none	UM-UC-3	SCID
[152]	5×10^7 pan $\gamma\delta$ T cells	i.v.	PBMC	single and repetitive	none	no	CNE2	BALB/c nude
[159]	1×10^7 V γ 9V δ 2	i.v.	PBMC	single	no	no	EBV induced B cell lymphoma	NSG

10. Perspective

More than a century after the groundbreaking work of Coley, the connection between immune responses geared to fight bacterial infection and its potential for tumor treatment is more prominent than ever. An increasing number of infection sensors and immune regulators are being explored for cancer therapy. This is reflected in the continuously growing global immune-oncology drug pipeline, which is currently led by immune checkpoint targeting biologics like PD-1 antagonists [127,167].

V γ 9V δ 2 T cells are a fascinating member of the immune cell landscape because, in addition to sensing of antigens through the variable parts of their TCRs, they have developed the unique ability to detect a specific PAMP with the invariable parts of their TCRs. Through binding to activated BTN3A, they are able to detect the intracellular appearance of a metabolic intermediate of the bacterial MEP pathway. This is a particularly clever invention of nature: virtually all bacteria have this pathway and, therefore, it is a unique feature for clear discrimination between self and foreign. BTN3A triggering gives an unrestrained order for elimination of the infected cell, and diverse infection models, most prominently those using *Mycobacterium tuberculosis* or *Listeria monocytogenes* pathogens, have demonstrated the efficiency and versatility of $\gamma\delta$ T effector cells. Recent breakthroughs, such as the elucidation of the BTN3A structure [13,18] or the 20.1 agonistic antibody [168], have provided mechanistic insight and tools and even prompted investigational therapeutic approaches. Not surprisingly, the pharmaceutical industry is increasingly interested, as reflected by the investments into the growing biotech field. However, as with all novel mechanisms, there is still a series of unknowns in the equation. In fact, the relative fraction of V γ 9V δ 2 T cells detected across tumor indications is relatively low [40] and it remains to be shown how they can be expanded to levels required for efficacy against a solid tumor. Moreover, it remains an open question whether system-wide activation will allow them to home in on and cross-link to tumor cells, which indeed is a pre-requisite for their elimination. Considering the pace at which the field is moving the answers might be at hand soon.

From initial adoptive transfer clinical trials, we know that V γ 9V δ 2 T cells are tolerated but the trials so far have not resulted in a therapeutic response in a significant number of individuals [88]. Next generation approaches will build on V γ 9V δ 2 T cell biology and find improvements, either in optimizations of adoptive transfer, clever off-the-shelf CAR-T approaches, or biologics that cross-link the tumor to a $\gamma\delta$ TCR.

In order to reliably detect and combat infection, nature does not rely on just a single immune sensor trip wire. Widening our focus to other innate immune sensors might help to improve the outcome of sole V γ 9V δ 2 T cell-activation. TLR agonists have shown synergies and abrogation of suppressive states in vitro [92,93], and cytokines, such as IL-2, could be explored further to evaluate their synergistic effects on effector cell activation and expansion. On the other side, sensory pathways are being discovered which might give additional or alternative therapeutic angles, such as the recently identified MR-1 specific cancer-selective TCR clone [169]. Finally, while there are many hurdles to be jumped, $\gamma\delta$ T cells with their high plasticity [27] represent a potential therapeutic option for a significant patient population with solid tumors.

From an immunological perspective, cancer has multiple similarities with chronic infection, where an efficient anti-pathogen response is stalled by evasion mechanisms and T cell-exhaustion. It is therefore intriguing to consider novel therapies, not only by activation of a single immunological aspect, but rather by mimicking an acute infection scenario, thereby providing the means to install the complex, endogenous immune responses necessary to eliminate diseased cells.

Author Contributions: Conceptualization, C.B.; Writing—Original draft preparation, C.B., K.-P.K., D.W.; Writing—review and editing, C.B., K.-P.K., D.W., H.-H.O., V.S., M.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: We are thankful to Mark Pearson for critically reviewing the manuscript and for constant and generous support, Günther Adolf, Dieter Kabelitz, Angelika Riedl, Daniel Szappanos and the DFG-sponsored $\gamma\delta$ T cell-research group FOR2799 for fruitful discussions.

Conflicts of Interest: The authors declare no competing financial interests.

References

- Decker, W.K.; Safdar, A. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. *Cytokine Growth Factor Rev.* **2009**, *20*, 271–281. [\[CrossRef\]](#) [\[PubMed\]](#)
- Falzone, L.; Salomone, S.; Libra, M. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. *Front. Pharm.* **2018**, *9*, 1300. [\[CrossRef\]](#)
- Lamm, D.L.; Blumenstein, B.A.; Crawford, E.D.; Montie, J.E.; Scardino, P.; Grossman, H.B.; Stanisic, T.H.; Smith, J.A.; Sullivan, J.; Sarosdy, M.F. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. *N. Engl. J. Med.* **1991**, *325*, 1205–1209. [\[CrossRef\]](#) [\[PubMed\]](#)
- Medzhitov, R.; Preston-Hurlburt, P.; Janeway, C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. *Nature* **1997**, *388*, 394–397. [\[CrossRef\]](#) [\[PubMed\]](#)
- Brubaker, S.W.; Bonham, K.S.; Zanoni, I.; Kagan, J.C. Innate immune pattern recognition: A cell biological perspective. *Annu. Rev. Immunol.* **2015**, *33*, 257–290. [\[CrossRef\]](#) [\[PubMed\]](#)
- Cho, Y.J.; Ahn, B.Y.; Lee, N.G.; Lee, D.H.; Kim, D.-S. A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy. *Vaccine* **2006**, *24*, 5862–5871. [\[CrossRef\]](#)
- Rakoff-Nahoum, S.; Medzhitov, R. Toll-like receptors and cancer. *Nat. Rev. Cancer* **2009**, *9*, 57–63. [\[CrossRef\]](#)
- Wei, M.Q.; Mengesha, A.; Good, D.; Anné, J. Bacterial targeted tumour therapy-dawn of a new era. *Cancer Lett.* **2008**, *259*, 16–27. [\[CrossRef\]](#)
- Braunstein, M.J.; Kucharczyk, J.; Adams, S. Targeting Toll-Like Receptors for Cancer Therapy. *Target Oncol* **2018**, *13*, 583–598. [\[CrossRef\]](#)
- Hennessy, E.J.; Parker, A.E.; O'Neill, L.A.J. Targeting Toll-like receptors: Emerging therapeutics? *Nat. Rev. Drug Discov.* **2010**, *9*, 293–307. [\[CrossRef\]](#)
- Mullard, A. Can innate immune system targets turn up the heat on “cold” tumours? *Nat. Rev. Drug Discov.* **2018**, *17*, 3–5. [\[CrossRef\]](#) [\[PubMed\]](#)
- Rhodes, D.A.; Chen, H.-C.; Price, A.J.; Keeble, A.H.; Davey, M.S.; James, L.C.; Eberl, M.; Trowsdale, J. Activation of human $\gamma\delta$ T cells by cytosolic interactions of BTN3A1 with soluble phosphoantigens and the cytoskeletal adaptor periplakin. *J. Immunol.* **2015**, *194*, 2390–2398. [\[CrossRef\]](#) [\[PubMed\]](#)
- Harly, C.; Guillaume, Y.; Nedellec, S.; Peigne, C.M.; Monkkenen, H.; Monkkenen, J.; Li, J.; Kuball, J.; Adams, E.J.; Netzer, S.; et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human T-cell subset. *Blood* **2012**, *120*, 2269–2279. [\[CrossRef\]](#) [\[PubMed\]](#)
- Sandstrom, A.; Peigné, C.-M.; Léger, A.; Crooks, J.E.; Konczak, F.; Gesnel, M.-C.; Breathnach, R.; Bonneville, M.; Scotet, E.; Adams, E.J. The Intracellular B30.2 Domain of Butyrophilin 3A1 Binds Phosphoantigens to Mediate Activation of Human V γ 9V δ 2 T Cells. *Immunity* **2014**, *40*, 490–500. [\[CrossRef\]](#)
- O'Neill, L.A.J.; Golenbock, D.; Bowie, A.G. The history of Toll-like receptors—Redefining innate immunity. *Nat. Rev. Immunol.* **2013**, *13*, 453–460. [\[CrossRef\]](#)
- Gu, S.; Nawrocka, W.; Adams, E.J. Sensing of Pyrophosphate Metabolites by V γ 9V δ 2 T Cells. *Front. Immunol.* **2014**, *5*, 688.
- Vavassori, S.; Kumar, A.; Wan, G.S.; Ramanjaneyulu, G.S.; Cavallari, M.; El Daker, S.; Beddoe, T.; Theodossis, A.; Williams, N.K.; Gostick, E.; et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human $\gamma\delta$ T cells. *Nat. Immunol.* **2013**, *14*, 908–916. [\[CrossRef\]](#)
- Gu, S.; Borowska, M.T.; Boughter, C.T.; Adams, E.J. Butyrophilin3A proteins and V γ 9V δ 2 T cell activation. *Semin. Cell Dev. Biol.* **2018**, *84*, 65–74. [\[CrossRef\]](#)
- Peigné, C.-M.; Léger, A.; Gesnel, M.-C.; Konczak, F.; Olive, D.; Bonneville, M.; Breathnach, R.; Scotet, E. The Juxtamembrane Domain of Butyrophilin BTN3A1 Controls Phosphoantigen-Mediated Activation of Human V γ 9V δ 2 T Cells. *J. Immunol.* **2017**, *198*, 4228–4234. [\[CrossRef\]](#)
- Sebestyen, Z.; Scheper, W.; Vyborova, A.; Gu, S.; Rychnavska, Z.; Schiffler, M.; Cleven, A.; Chéneau, C.; van Noorden, M.; Peigné, C.-M.; et al. RhoB Mediates Phosphoantigen Recognition by V γ 9V δ 2 T Cell Receptor. *CellReports* **2016**, *15*, 1973–1985. [\[CrossRef\]](#)
- De Libero, G.; Lau, S.-Y.; Mori, L. Phosphoantigen Presentation to TCR $\gamma\delta$ Cells, a Conundrum Getting Less Gray Zones. *Front. Immunol.* **2014**, *5*, 679.

22. Gruenbacher, G.; Gander, H.; Rahm, A.; Idzko, M.; Nussbaumer, O.; Thurnher, M. Ecto-ATPase CD39 Inactivates Isoprenoid-Derived V γ 9V δ 2 T Cell Phosphoantigens. *CellReports* **2016**, *16*, 444–456. [[CrossRef](#)]
23. Riaño, F.; Karunakaran, M.M.; Starick, L.; Li, J.; Scholz, C.J.; Kunzmann, V.; Olive, D.; Amslinger, S.; Herrmann, T. V γ 9V δ 2 TCR-activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6. *Eur. J. Immunol.* **2014**, *44*, 2571–2576. [[CrossRef](#)] [[PubMed](#)]
24. Rigau, M.; Ostrouska, S.; Fulford, T.S.; Johnson, D.N.; Woods, K.; Ruan, Z.; McWilliam, H.E.G.; Hudson, C.; Tutuka, C.; Wheatley, A.K.; et al. Butyrophilin 2A1 is essential for phosphoantigen reactivity by $\gamma\delta$ T cells. *Science* **2020**, eaay5516. [[CrossRef](#)] [[PubMed](#)]
25. Karunakaran, M.M.; Willcox, C.R.; Salim, M.; Paletta, D.; Fichtner, A.S.; Noll, A.; Starick, L.; Nöhren, A.; Begley, C.R.; Berwick, K.A.; et al. Butyrophilin-2A1 Directly Binds Germline-Encoded Regions of the V γ 9V δ 2 TCR and Is Essential for Phosphoantigen Sensing. *Immunity* **2020**, *52*, 487–498.e6. [[CrossRef](#)] [[PubMed](#)]
26. Willcox, B.E.; Willcox, C.R. $\gamma\delta$ TCR ligands: The quest to solve a 500-million-year-old mystery. *Nat. Immunol.* **2019**, *20*, 1–8. [[CrossRef](#)]
27. Melandri, D.; Zlatareva, I.; Chaleil, R.A.G.; Dart, R.J.; Chancellor, A.; Nussbaumer, O.; Polyakova, O.; Roberts, N.A.; Wesch, D.; Kabelitz, D.; et al. The $\gamma\delta$ TCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness. *Nat. Immunol.* **2018**, *19*, 1352–1365. [[CrossRef](#)] [[PubMed](#)]
28. Ferreira, L.M.R. Gammadelta T cells: Innately adaptive immune cells? *Int. Rev. Immunol.* **2013**, *32*, 223–248. [[CrossRef](#)]
29. Perera, M.K.; Carter, R.; Goonewardene, R.; Mendis, K.N. Transient increase in circulating gamma/delta T cells during Plasmodium vivax malarial paroxysms. *J. Exp. Med.* **1994**, *179*, 311–315. [[CrossRef](#)]
30. Raziuddin, S.; Telmasani, A.W.; el-Hag el-Awad, M.; al-Amari, O.; al-Janadi, M. Gamma delta T cells and the immune response in visceral leishmaniasis. *Eur. J. Immunol.* **1992**, *22*, 1143–1148. [[CrossRef](#)]
31. Jouen-Beades, F.; Paris, E.; Dieulois, C.; Lemeland, J.F.; Barre-Dezelus, V.; Marret, S.; Humbert, G.; Leroy, J.; Tron, F. In vivo and in vitro activation and expansion of gammadelta T cells during Listeria monocytogenes infection in humans. *Infect. Immun.* **1997**, *65*, 4267–4272. [[CrossRef](#)] [[PubMed](#)]
32. Sumida, T.; Maeda, T.; Takahashi, H.; Yonaha, F.; Sakamoto, A.; Tomioka, H.; Koike, T.; YOSHIDA, S. Predominant expansion of V gamma 9/V delta 2 T cells in a tularemia patient. *Infect. Immun.* **1992**, *60*, 2554–2558. [[CrossRef](#)] [[PubMed](#)]
33. Gil, O.; Guirado, E.; Gordillo, S.; Díaz, J.; Tapia, G.; Vilaplana, C.; Ariza, A.; Ausina, V.; Cardona, P.-J. Intragranulomatous necrosis in lungs of mice infected by aerosol with Mycobacterium tuberculosis is related to bacterial load rather than to any one cytokine or T cell type. *Microbes Infect.* **2006**, *8*, 628–636. [[CrossRef](#)]
34. Behar, S.M.; Porcelli, S.A. CD1-restricted T cells in host defense to infectious diseases. *Curr. Top. Microbiol. Immunol.* **2007**, *314*, 215–250. [[PubMed](#)]
35. Kabelitz, D.; Bender, A.; Prospero, T.; Wesselborg, S.; Janssen, O.; Pechhold, K. The primary response of human gamma/delta + T cells to Mycobacterium tuberculosis is restricted to V gamma 9-bearing cells. *J. Exp. Med.* **1991**, *173*, 1331–1338.
36. Havlir, D.V.; Ellner, J.J.; Chervenak, K.A.; Boom, W.H. Selective expansion of human gamma delta T cells by monocytes infected with live Mycobacterium tuberculosis. *J. Clin. Invest.* **1991**, *87*, 729–733. [[CrossRef](#)]
37. Ryan-Payseur, B.; Frencher, J.; Shen, L.; Chen, C.Y.; Huang, D.; Chen, Z.W. Multieffector-Functional Immune Responses of HMBPP-Specific V γ 2V δ 2 T Cells in Nonhuman Primates Inoculated with Listeria monocytogenes Δ actA prfA*. *J. Immunol.* **2012**, *189*, 1285–1293. [[CrossRef](#)]
38. Shen, Y.; Zhou, D.; Qiu, L.; Lai, X.; Simon, M.; Shen, L.; Kou, Z.; Wang, Q.; Jiang, L.; Estep, J.; et al. Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections. *Science* **2002**, *295*, 2255–2258. [[CrossRef](#)]
39. Gentles, A.J.; Newman, A.M.; Liu, C.L.; Bratman, S.V.; Feng, W.; Kim, D.; Nair, V.S.; Xu, Y.; Khuong, A.; Hoang, C.D.; et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. *Nat. Med.* **2015**, *1*–12. [[CrossRef](#)]
40. Tosolini, M.; Pont, F.; Poupot, M.; Vergez, F.; Nicolau-Travers, M.-L.; Vermijlen, D.; Sarry, J.E.; Dieli, F.; Fournié, J.-J. Assessment of tumor-infiltrating TCRV γ 9V δ 2 $\gamma\delta$ lymphocyte abundance by deconvolution of human cancers microarrays. *Oncoimmunology* **2017**, *6*, 1–10. [[CrossRef](#)]

41. Scotet, E.; Martinez, L.O.; Grant, E.; Barbaras, R.; Jenö, P.; Guiraud, M.; Monsarrat, B.; Saulquin, X.; Maillet, S.; Estève, J.-P.; et al. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. *Immunity* **2005**, *22*, 71–80. [\[CrossRef\]](#) [\[PubMed\]](#)
42. Dai, Y.; Chen, H.; Mo, C.; Cui, L.; He, W. Ectopically expressed human tumor biomarker MutS homologue 2 is a novel endogenous ligand that is recognized by human $\gamma\delta$ T cells to induce innate anti-tumor/virus immunity. *J. Biol. Chem.* **2012**, *287*, 16812–16819. [\[CrossRef\]](#) [\[PubMed\]](#)
43. Gober, H.-J.; Kistowska, M.; Angman, L.; Jenö, P.; Mori, L.; De Libero, G. Human T Cell Receptor $\gamma\delta$ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells. *J. Exp. Med.* **2003**, *197*, 163–168. [\[CrossRef\]](#) [\[PubMed\]](#)
44. Morita, C.T.; Jin, C.; Sarikonda, G.; Wang, H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: Discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. *Immunol. Rev.* **2007**, *215*, 59–76. [\[PubMed\]](#)
45. Benzaïd, I.; Mönkkönen, H.; Stresing, V.; Bonnelye, E.; Green, J.; Mönkkönen, J.; Touraine, J.-L.; Clézardin, P. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. *Cancer Res.* **2011**, *71*, 4562–4572. [\[CrossRef\]](#) [\[PubMed\]](#)
46. Jauhainen, M.; Mönkkönen, H.; Räikkönen, J.; Mönkkönen, J.; Auriola, S. Analysis of endogenous ATP analogs and mevalonate pathway metabolites in cancer cell cultures using liquid chromatography-electrospray ionization mass spectrometry. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* **2009**, *877*, 2967–2975. [\[CrossRef\]](#)
47. Bryant, N.L.; Suarez-Cuervo, C.; Gillespie, G.Y.; Markert, J.M.; Nabors, L.B.; Meleth, S.; Lopez, R.D.; Lamb, L.S. Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. *Neuro-Oncol.* **2009**, *11*, 357–367. [\[CrossRef\]](#)
48. Rey, J.; Veuillen, C.; Vey, N.; Bouabdallah, R.; Olive, D. Natural killer and $\gamma\delta$ T cells in haematological malignancies: Enhancing the immune effectors. *Trends Mol. Med.* **2009**, *15*, 275–284. [\[CrossRef\]](#)
49. Todaro, M.; D’Asaro, M.; Caccamo, N.; Iovino, F.; Francipane, M.G.; Meraviglia, S.; Orlando, V.; La Mendola, C.; Gulotta, G.; Salerno, A.; et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. *J. Immunol.* **2009**, *182*, 7287–7296. [\[CrossRef\]](#)
50. Yuasa, T.; Sato, K.; Ashihara, E.; Takeuchi, M.; Maita, S.; Tsuchiya, N.; Habuchi, T.; Maekawa, T.; Kimura, S. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. *Cancer Immunol. Immunother.* **2009**, *58*, 493–502. [\[CrossRef\]](#)
51. Banerjee, S.; Tian, T.; Wei, Z.; Shih, N.; Feldman, M.D.; Peck, K.N.; DeMichele, A.M.; Alwine, J.C.; Robertson, E.S. Distinct Microbial Signatures Associated with Different Breast Cancer Types. *Front. Microbiol.* **2018**, *9*, 1–20. [\[CrossRef\]](#) [\[PubMed\]](#)
52. Cogdill, A.P.; Gaudreau, P.O.; Arora, R.; Gopalakrishnan, V.; Wargo, J.A. The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. *Trends Immunol.* **2018**, *39*, 900–920. [\[CrossRef\]](#) [\[PubMed\]](#)
53. Banerjee, S.; Tian, T.; Wei, Z.; Peck, K.N.; Shih, N.; Chalian, A.A.; O’Malley, B.W.; Weinstein, G.S.; Feldman, M.D.; Alwine, J.; et al. Microbial Signatures Associated with Oropharyngeal and Oral Squamous Cell Carcinomas. *Sci. Rep.* **2017**, *7*, 135–20. [\[CrossRef\]](#) [\[PubMed\]](#)
54. Redelman-Sidi, G.; Iyer, G.; Solit, D.B.; Glickman, M.S. Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells. *Cancer Res.* **2013**, *73*, 1156–1167. [\[CrossRef\]](#)
55. Geller, L.T.; Barzily-Rokni, M.; Danino, T.; Jonas, O.H.; Shental, N.; Nejman, D.; Gavert, N.; Zwang, Y.; Cooper, Z.A.; Shee, K.; et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. *Science* **2017**, *357*, 1156–1160. [\[CrossRef\]](#)
56. Bezine, E.; Vignard, J.; Mirey, G. The Cytotoxic Distending Toxin Effects on Mammalian Cells: A DNA Damage Perspective. *Cells* **2014**, *3*, 592–615. [\[CrossRef\]](#)
57. Healy, A.R.; Nikolayevskiy, H.; Patel, J.R.; Crawford, J.M.; Herzon, S.B. A Mechanistic Model for Colibactin-Induced Genotoxicity. *J. Am. Chem. Soc.* **2016**, *138*, 15563–15570. [\[CrossRef\]](#)
58. Gur, C.; Ibrahim, Y.; Isaacson, B.; Yamin, R.; Abed, J.; Gamliel, M.; Enk, J.; Bar-On, Y.; Stanietsky-Kaynan, N.; Copenhagen-Glazer, S.; et al. Binding of the Fap2 Protein of *Fusobacterium nucleatum* to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack. *Immunity* **2015**, *42*, 344–355. [\[CrossRef\]](#)
59. Rubinstein, M.R.; Wang, X.; Liu, W.; Hao, Y.; Cai, G.; Han, Y.W. *Fusobacterium nucleatum* Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/ β -Catenin Signaling via its FadA Adhesin. *Cell Host. Microbe.* **2013**, *14*, 195–206. [\[CrossRef\]](#)

60. Spada, F.M.; Grant, E.P.; Peters, P.J.; Sugita, M.; Melián, A.; Leslie, D.S.; Lee, H.K.; van Donselaar, E.; Hanson, D.A.; Krensky, A.M.; et al. Self-recognition of CD1 by gamma/delta T cells: Implications for innate immunity. *J. Exp. Med.* **2000**, *191*, 937–948. [\[CrossRef\]](#)
61. Caccamo, N.; Dieli, F.; Meraviglia, S.; Guggino, G.; Salerno, A. Gammadelta T cell modulation in anticancer treatment. *Curr. Cancer Drug Targets* **2010**, *10*, 27–36. [\[CrossRef\]](#) [\[PubMed\]](#)
62. Dieli, F.; Troye-Blomberg, M.; Ivanyi, J.; Fournie, J.J.; Krensky, A.M.; Bonneville, M.; Peyrat, M.A.; Caccamo, N.; Sireci, G.; Salerno, A. Granulysin-dependent killing of intracellular and extracellular *Mycobacterium tuberculosis* by Vgamma9/Vdelta2 T lymphocytes. *J. Infect. Dis.* **2001**, *184*, 1082–1085. [\[CrossRef\]](#) [\[PubMed\]](#)
63. Spencer, C.T.; Abate, G.; Sakala, I.G.; Xia, M.; Truscott, S.M.; Eickhoff, C.S.; Linn, R.; Blazevic, A.; Metkar, S.S.; Peng, G.; et al. Granzyme A produced by $\gamma(9)\delta(2)$ T cells induces human macrophages to inhibit growth of an intracellular pathogen. *Plos Pathog.* **2013**, *9*, e1003119. [\[CrossRef\]](#) [\[PubMed\]](#)
64. Oberg, H.-H.; Janitschke, L.; Sulaj, V.; Weimer, J.; Gonnermann, D.; Hedemann, N.; Arnold, N.; Kabelitz, D.; Peipp, M.; Bauerschlag, D.; et al. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors. *J. Leukoc. Biol.* **2019**. [\[CrossRef\]](#) [\[PubMed\]](#)
65. Couzi, L.; Pitard, V.; Sicard, X.; Garrigue, I.; Hawchar, O.; Merville, P.; Moreau, J.-F.; Déchanet-Merville, J. Antibody-dependent anti-cytomegalovirus activity of human $\gamma\delta$ T cells expressing CD16 (Fc γ RIIIa). *Blood* **2012**, *119*, 1418–1427. [\[CrossRef\]](#)
66. Gertner-Dardenne, J.; Bonnafous, C.; Bezombes, C.; Capietto, A.-H.; Scaglione, V.; Ingoure, S.; Cendron, D.; Gross, E.; Lepage, J.-F.; Quillet-Mary, A.; et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. *Blood* **2009**, *113*, 4875–4884. [\[CrossRef\]](#)
67. Hoeres, T.; Pretscher, D.; Holzmann, E.; Smetak, M.; Birkmann, J.; Triebel, J.; Bertsch, T.; Wilhelm, M. Improving Immunotherapy Against B-Cell Malignancies Using $\gamma\delta$ T-Cell-specific Stimulation and Therapeutic Monoclonal Antibodies. *J. Immunother.* **2019**, *42*, 331–344. [\[CrossRef\]](#)
68. Zoine, J.T.; Knight, K.A.; Fleischer, L.C.; Sutton, K.S.; Goldsmith, K.C.; Doering, C.B.; Spencer, H.T. Ex vivo expanded patient-derived $\gamma\delta$ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model. *Oncoimmunology* **2019**, *8*, 1–13. [\[CrossRef\]](#)
69. Capietto, A.-H.; Martinet, L.; Fournié, J.-J. Stimulated $\gamma\delta$ T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer. *J. Immunol.* **2011**, *187*, 1031–1038. [\[CrossRef\]](#)
70. Oberg, H.H.; Kellner, C.; Gonnermann, D.; Sebens, S.; Bauerschlag, D.; Gramatzki, M.; Kabelitz, D.; Peipp, M.; Wesch, D. Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing $\gamma\delta$ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. *Front. Immunol.* **2018**, *9*, 814. [\[CrossRef\]](#)
71. Brandes, M.; Willmann, K.; Bioley, G.; Lévy, N.; Eberl, M.; Luo, M.; Tampé, R.; Lévy, F.; Romero, P.; Moser, B. Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 2307–2312. [\[CrossRef\]](#) [\[PubMed\]](#)
72. Brandes, M.; Willmann, K.; Moser, B. Professional antigen-presentation function by human gammadelta T Cells. *Science* **2005**, *309*, 264–268. [\[CrossRef\]](#) [\[PubMed\]](#)
73. Eggermont, L.J.; Paulis, L.E.; Tel, J.; Figdor, C.G. Towards efficient cancer immunotherapy: Advances in developing artificial antigen-presenting cells. *Trends Biotechnol.* **2014**, *32*, 456–465. [\[CrossRef\]](#) [\[PubMed\]](#)
74. Kastenmüller, W.; Kastenmüller, K.; Kurts, C.; Seder, R.A. Dendritic cell-targeted vaccines—Hope or hype? *Nat. Rev. Immunol.* **2014**, *14*, 705–711.
75. Himoudi, N.; Morgenstern, D.A.; Yan, M.; Vernay, B.; Saraiva, L.; Wu, Y.; Cohen, C.J.; Gustafsson, K.; Anderson, J. Human $\gamma\delta$ T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. *J. Immunol.* **2012**, *188*, 1708–1716. [\[CrossRef\]](#)
76. Shen, L.; Frencher, J.; Huang, D.; Wang, W.; Yang, E.; Chen, C.Y.; Zhang, Z.; Wang, R.; Qaqish, A.; Larsen, M.H.; et al. Immunization of V γ 2V δ 2 T cells programs sustained effector memory responses that control tuberculosis in nonhuman primates. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 6371–6378. [\[CrossRef\]](#)
77. Shao, L.; Huang, D.; Wei, H.; Wang, R.C.; Chen, C.Y.; Shen, L.; Zhang, W.; Jin, J.; Chen, Z.W. Expansion, reexpansion, and recall-like expansion of V γ 9V δ 2 T cells in smallpox vaccination and monkeypox virus infection. *J. Virol.* **2009**, *83*, 11959–11965. [\[CrossRef\]](#)
78. Sicard, H.; Ingoure, S.; Luciani, B.; Serraz, C.; Fournié, J.-J.; Bonneville, M.; Tiollier, J.; Romagné, F. In vivo immunomanipulation of V γ 9V δ 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. *J. Immunol.* **2005**, *175*, 5471–5480. [\[CrossRef\]](#)

79. Wang, L.; Kamath, A.; Das, H.; Li, L.; Bukowski, J.F. Antibacterial effect of human V γ 2V δ 2 T cells in vivo. *J. Clin. Invest.* **2001**, *108*, 1349–1357. [[CrossRef](#)]
80. Huang, D.; Shen, Y.; Qiu, L.; Chen, C.Y.; Shen, L.; Estep, J.; Hunt, R.; Vasconcelos, D.; Du, G.; Aye, P.; et al. Immune Distribution and Localization of Phosphoantigen-Specific V γ 2V δ 2 T Cells in Lymphoid and Nonlymphoid Tissues in Mycobacterium tuberculosis Infection. *Infect. Immun.* **2008**, *76*, 426–436. [[CrossRef](#)]
81. Caccamo, N.; Todaro, M.; Sireci, G.; Meraviglia, S.; Stassi, G.; Dieli, F. Mechanisms underlying lineage commitment and plasticity of human $\gamma\delta$ T cells. *Cell. Mol. Immunol.* **2013**, *10*, 30–34. [[CrossRef](#)] [[PubMed](#)]
82. Traxlmayr, M.W.; Wesch, D.; Dohnal, A.M.; Funovics, P.; Fischer, M.B.; Kabelitz, D.; Felzmann, T. Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cells. *J. Immunother.* **2010**, *33*, 40–52. [[CrossRef](#)] [[PubMed](#)]
83. Peters, C.; Oberg, H.-H.; Kabelitz, D.; Wesch, D. Phenotype and regulation of immunosuppressive V δ 2-expressing $\gamma\delta$ T cells. *Cell. Mol. Life Sci.* **2013**, *71*, 1943–1960. [[CrossRef](#)] [[PubMed](#)]
84. Peters, C.; Meyer, A.; Kouakanou, L.; Feder, J.; Schrick, T.; Lettau, M.; Janssen, O.; Wesch, D.; Kabelitz, D. TGF- β enhances the cytotoxic activity of V δ 2 T cells. *Oncoimmunology* **2019**, *8*, e1522471. [[CrossRef](#)]
85. Wesch, D.; Peters, C.; Siegers, G.M. Human gamma delta T regulatory cells in cancer: Fact or fiction? *Front. Immunol.* **2014**, *5*, 598. [[CrossRef](#)]
86. Wu, P.; Wu, D.; Ni, C.; Ye, J.; Chen, W.; Hu, G.; Wang, Z.; Wang, C.; Zhang, Z.; Xia, W.; et al. $\gamma\delta$ T17 Cells Promote the Accumulation and Expansion of Myeloid-Derived Suppressor Cells in Human Colorectal Cancer. *Immunity* **2014**, *40*, 785–800. [[CrossRef](#)]
87. Ye, J.; Ma, C.; Wang, F.; Hsueh, E.C.; Toth, K.; Huang, Y.; Mo, W.; Liu, S.; Han, B.; Varvares, M.A.; et al. Specific recruitment of $\gamma\delta$ regulatory T cells in human breast cancer. *Cancer Res.* **2013**, *73*, 6137–6148. [[CrossRef](#)]
88. Meraviglia, S.; Eberl, M.; Vermijlen, D.; Todaro, M.; Buccheri, S.; Cicero, G.; La Mendola, C.; Guggino, G.; D'Asaro, M.; Orlando, V.; et al. In vivo manipulation of V γ 9V δ 2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. *Clin. Exp. Immunol.* **2010**, *161*, 290–297. [[CrossRef](#)]
89. Dieli, F.; Vermijlen, D.; Fulfaro, F.; Caccamo, N.; Meraviglia, S.; Cicero, G.; Roberts, A.; Buccheri, S.; D'Asaro, M.; Gebbia, N.; et al. Targeting Human T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer. *Cancer Res.* **2007**, *67*, 7450–7457. [[CrossRef](#)]
90. Shojaei, H.; Oberg, H.-H.; Juricke, M.; Marischen, L.; Kunz, M.; Mundhenke, C.; Gieseler, F.; Kabelitz, D.; Wesch, D. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. *Cancer Res.* **2009**, *69*, 8710–8717. [[CrossRef](#)]
91. Wesch, D.; Beetz, S.; Oberg, H.-H.; Marget, M.; Krengel, K.; Kabelitz, D. Direct costimulatory effect of TLR3 ligand poly(I:C) on human gamma delta T lymphocytes. *J. Immunol.* **2006**, *176*, 1348–1354. [[PubMed](#)]
92. Pietschmann, K.; Beetz, S.; Welte, S.; Martens, I.; Gruen, J.; Oberg, H.H.; Wesch, D.; Kabelitz, D. Toll-like receptor expression and function in subsets of human gammadelta T lymphocytes. *Scand. J. Immunol.* **2009**, *70*, 245–255. [[CrossRef](#)] [[PubMed](#)]
93. Wesch, D.; Peters, C.; Oberg, H.-H.; Pietschmann, K.; Kabelitz, D. Modulation of $\gamma\delta$ T cell responses by TLR ligands. *Cell. Mol. Life Sci. (CMLS)* **2011**, *68*, 2357–2370. [[CrossRef](#)] [[PubMed](#)]
94. Gong, G.; Shao, L.; Wang, Y.; Chen, C.Y.; Huang, D.; Yao, S.; Zhan, X.; Sicard, H.; Wang, R.; Chen, Z.W. Phosphoantigen-activated V gamma 2V delta 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection. *Blood* **2009**, *113*, 837–845. [[CrossRef](#)] [[PubMed](#)]
95. Lo Presti, E.; Pizzolato, G.; Corsale, A.M.; Caccamo, N.; Sireci, G.; Dieli, F.; Meraviglia, S. $\gamma\delta$ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion. *Front. Immunol.* **2018**, *9*, 1395. [[CrossRef](#)]
96. Wu, D.; Wu, P.; Qiu, F.; Wei, Q.; Huang, J. Human $\gamma\delta$ T-cell subsets and their involvement in tumor immunity. *Cell. Mol. Immunol.* **2016**, *14*, 245–253. [[CrossRef](#)]
97. Wang, R.N.; Wen, Q.; He, W.T.; Yang, J.H.; Zhou, C.Y.; Xiong, W.J.; Ma, L. Optimized protocols for $\gamma\delta$ T cell expansion and lentiviral transduction. *Mol. Med. Rep.* **2019**, 1–10. [[CrossRef](#)]
98. Rådestad, E.; Klynning, C.; Stikvoort, A.; Mogensen, O.; Nava, S.; Magalhaes, I.; Uhlin, M. Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer. *Oncoimmunology* **2019**, *8*, e1535730. [[CrossRef](#)]

99. Aoki, T.; Matsushita, H.; Hoshikawa, M.; Hasegawa, K.; Kokudo, N.; Kakimi, K. Adjuvant combination therapy with gemcitabine and autologous $\gamma\delta$ T-cell transfer in patients with curatively resected pancreatic cancer. *Cytotherapy* **2017**, *19*, 473–485. [\[CrossRef\]](#)
100. Kobayashi, H.; Tanaka, Y.; Yagi, J.; Osaka, Y.; Nakazawa, H.; Uchiyama, T.; Minato, N.; Toma, H. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: A pilot study. *Cancer Immunol. Immunother.* **2006**, *56*, 469–476. [\[CrossRef\]](#)
101. Kobayashi, H.; Tanaka, Y.; Yagi, J.; Minato, N.; Tanabe, K. Phase I/II study of adoptive transfer of $\gamma\delta$ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. *Cancer Immunol. Immunother.* **2011**, *60*, 1075–1084. [\[CrossRef\]](#) [\[PubMed\]](#)
102. Wada, I.; Matsushita, H.; Noji, S.; Mori, K.; Yamashita, H.; Nomura, S.; Shimizu, N.; Seto, Y.; Kakimi, K. Intraperitoneal injection of in vitro expanded V γ 9V δ 2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. *Cancer Med* **2014**, *3*, 362–375. [\[CrossRef\]](#) [\[PubMed\]](#)
103. Izumi, T.; Kondo, M.; Takahashi, T.; Fujieda, N.; Kondo, A.; Tamura, N.; Murakawa, T.; Nakajima, J.; Matsushita, H.; Kakimi, K. Ex vivo characterization of $\gamma\delta$ T-cell repertoire in patients after adoptive transfer of V γ 9V δ 2 T cells expressing the interleukin-2 receptor β -chain and the common γ -chain. *Cytotherapy* **2013**, *15*, 481–491. [\[CrossRef\]](#) [\[PubMed\]](#)
104. Wilhelm, M.; Smetak, M.; Schaefer-Eckart, K.; Kimmel, B.; Birkmann, J.; Einsele, H.; Kunzmann, V. Successful adoptive transfer and in vivo expansion of haploidentical $\gamma\delta$ T cells. *J. Transl. Med.* **2014**, *12*, 45. [\[CrossRef\]](#)
105. Bennouna, J.; Bompas, E.; Neidhardt, E.M.; Rolland, F.; Philip, I.; Gal  a, C.; Salot, S.; Saiagh, S.; Audrain, M.; Rimbart, M.; et al. Phase-I study of Innacell $\gamma\delta$ TM, an autologous cell-therapy product highly enriched in γ 9 δ 2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. *Cancer Immunol. Immunother.* **2008**, *57*, 1599–1609. [\[CrossRef\]](#)
106. Abe, Y.; Muto, M.; Nieda, M.; Nakagawa, Y.; Nicol, A.; Kaneko, T.; Goto, S.; Yokokawa, K.; Suzuki, K. Clinical and immunological evaluation of zoledronate-activated V γ 9 gamma delta T-cell-based immunotherapy for patients with multiple myeloma. *Exp. Hematol.* **2009**, *37*, 956–968. [\[CrossRef\]](#)
107. Nakajima, J.; Murakawa, T.; Fukami, T.; Goto, S.; Kaneko, T.; Yoshida, Y.; Takamoto, S.; Kakimi, K. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gamma delta T cells. *Eur. J. Cardiothorac. Surg.* **2010**, *37*, 1191–1197. [\[CrossRef\]](#)
108. Nicol, A.J.; Tokuyama, H.; Mattarollo, S.R.; Hagi, T.; Suzuki, K.; Yokokawa, K.; Nieda, M. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. *Br. J. Cancer* **2011**, *105*, 778–786. [\[CrossRef\]](#)
109. Noguchi, A.; Kaneko, T.; Kamigaki, T.; Fujimoto, K.; Ozawa, M.; Saito, M.; Ariyoshi, N.; Goto, S. Zoledronate-activated V γ 9 $\gamma\delta$ T cell-based immunotherapy is feasible and restores the impairment of $\gamma\delta$ T cells in patients with solid tumors. *Cytotherapy* **2011**, *13*, 92–97. [\[CrossRef\]](#)
110. Sakamoto, M.; Nakajima, J.; Murakawa, T.; Fukami, T.; Yoshida, Y.; Murayama, T.; Takamoto, S.; Matsushita, H.; Kakimi, K. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded $\gamma\delta$ T cells: A phase I clinical study. *J. Immunother.* **2011**, *34*, 202–211. [\[CrossRef\]](#)
111. Cui, J.; Wang, N.; Zhao, H.; Jin, H.; Wang, G.; Niu, C.; Terunuma, H.; He, H.; Li, W. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. *Int. J. Cancer* **2014**, *134*, 342–351. [\[CrossRef\]](#) [\[PubMed\]](#)
112. Wilhelm, M.; Kunzmann, V.; Eckstein, S.; Reimer, P.; Weissinger, F.; Ruediger, T.; Tony, H.-P. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. *Blood* **2003**, *102*, 200–206. [\[CrossRef\]](#) [\[PubMed\]](#)
113. Lang, J.M.; Kaikobad, M.R.; Wallace, M.; Staab, M.J.; Horvath, D.L.; Wilding, G.; Liu, G.; Eickhoff, J.C.; McNeel, D.G.; Malkovsky, M. Pilot trial of interleukin-2 and zoledronic acid to augment $\gamma\delta$ T cells as treatment for patients with refractory renal cell carcinoma. *Cancer Immunol. Immunother.* **2011**, *60*, 1447–1460. [\[CrossRef\]](#) [\[PubMed\]](#)
114. Cooper, L.J.N. Clinical applications of gamma delta T cells with multivalent immunity. *Front. Immunol.* **2014**, 1–10.
115. Bennouna, J.; Levy, V.; Sicard, H.; Senellart, H.; Audrain, M.; Hiret, S.; Rolland, F.; Bruzzoni-Giovanelli, H.; Rimbart, M.; Gal  a, C.; et al. Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a V γ 9V δ 2 T lymphocyte agonist in patients with solid tumors. *Cancer Immunol. Immunother.* **2010**, *59*, 1521–1530. [\[CrossRef\]](#)

116. Kunzmann, V.; Smetak, M.; Kimmel, B.; Weigang-Koehler, K.; Goebeler, M.; Birkmann, J.; Becker, J.; Schmidt-Wolf, I.G.H.; Einsele, H.; Wilhelm, M. Tumor-promoting versus tumor-antagonizing roles of $\gamma\delta$ T cells in cancer immunotherapy: Results from a prospective phase I/II trial. *J. Immunother.* **2012**, *35*, 205–213. [\[CrossRef\]](#)
117. Pressey, J.G.; Adams, J.; Harkins, L.; Kelly, D.; You, Z.; Lamb, L.S. In vivo expansion and activation of $\gamma\delta$ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study. *Med. (Baltim.)* **2016**, *95*, e4909. [\[CrossRef\]](#)
118. Brown, C.E.; Mackall, C.L. CAR T cell therapy: Inroads to response and resistance. *Nat. Rev. Immunol.* **2019**, *19*, 73–74. [\[CrossRef\]](#)
119. Capsomidis, A.; Benthall, G.; Van Acker, H.H.; Fisher, J.; Kramer, A.M.; Abeln, Z.; Majani, Y.; Gileadi, T.; Wallace, R.; Gustafsson, K.; et al. Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation. *Mol. Ther.* **2018**, *26*, 354–365. [\[CrossRef\]](#)
120. Benyamine, A.; Loncle, C.; Foucher, E.; Blazquez, J.-L.; Castanier, C.; Chrétien, A.-S.; Modesti, M.; Secq, V.; Chouaib, S.; Gironella, M.; et al. BTN3A is a prognosis marker and a promising target for V γ 9V δ 2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). *Oncoimmunology* **2017**, *0*, 1–14. [\[CrossRef\]](#)
121. Palakodeti, A.; Sandstrom, A.; Sundaresan, L.; Harly, C.; Nedellec, S.; Olive, D.; Scotet, E.; Bonneville, M.; Adams, E.J. The Molecular Basis for Modulation of Human V γ 9V δ 2 T Cell Responses by CD277/Butyrophilin-3 (BTN3A)-specific Antibodies. *J. Biol. Chem.* **2012**, *287*, 32780–32790. [\[CrossRef\]](#) [\[PubMed\]](#)
122. Benyamine, A.; Le Roy, A.; Mamessier, E.; Gertner-Dardenne, J.; Castanier, C.; Orlanducci, F.; Pouyet, L.; Goubard, A.; Collette, Y.; Vey, N.; et al. BTN3A molecules considerably improve V γ 9V δ 2T cells-based immunotherapy in acute myeloid leukemia. *Oncoimmunology* **2016**, *5*, 1–10. [\[CrossRef\]](#) [\[PubMed\]](#)
123. Martinelli, G.; Boissel, N.; Chevallier, P.; Ottmann, O.; Gökbuget, N.; Topp, M.S.; Fielding, A.K.; Rambaldi, A.; Ritchie, E.K.; Papayannidis, C.; et al. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. *J. Clin. Oncol.* **2017**, *35*, 1795–1802. [\[CrossRef\]](#) [\[PubMed\]](#)
124. Yuraszeck, T.; Kasichayanula, S.; Benjamin, J.E. Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment. *Clin. Pharmacol. Ther.* **2017**, *101*, 634–645. [\[CrossRef\]](#)
125. Nagorsen, D.; Kufer, P.; Baeuerle, P.A.; Bargou, R. Blinatumomab: A historical perspective. *Pharmacol. Ther.* **2012**, *136*, 334–342. [\[CrossRef\]](#)
126. Klinger, M.; Brandl, C.; Zugmaier, G.; Hijazi, Y.; Bargou, R.C.; Topp, M.S.; Gökbuget, N.; Neumann, S.; Goebeler, M.; Viardot, A.; et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. *Blood* **2012**, *119*, 6226–6233. [\[CrossRef\]](#)
127. Tang, J.; Pearce, L.; O'Donnell-Tormey, J.; Hubbard-Lucey, V.M. Trends in the global immuno-oncology landscape. *Nat. Rev. Drug Discov.* **2018**, *17*, 783–784. [\[CrossRef\]](#)
128. Kebenko, M.; Goebeler, M.-E.; Wolf, M.; Hasenburg, A.; Seggewiss-Bernhardt, R.; Ritter, B.; Rautenberg, B.; Atanackovic, D.; Kratzer, A.; Rottman, J.B.; et al. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. *Oncoimmunology* **2018**, *7*, e1450710.
129. Thorsson, V.; Gibbs, D.L.; Brown, S.D.; Wolf, D.; Bortone, D.S.; Yang, T.-H.O.; Porta-Pardo, E.; Gao, G.F.; Plaisier, C.L.; Eddy, J.A.; et al. The Immune Landscape of Cancer. *Immunity* **2018**, *48*, 812–830.e14. [\[CrossRef\]](#)
130. Kobold, S.; Pantelyushin, S.; Rataj, F.; Vom Berg, J. Rationale for Combining Bispecific T Cell Activating Antibodies with Checkpoint Blockade for Cancer Therapy. *Front. Oncol.* **2018**, *8*, 285. [\[CrossRef\]](#)
131. Marshall, H.T.; Djamgoz, M.B.A. Immuno-Oncology: Emerging Targets and Combination Therapies. *Front. Oncol.* **2018**, *8*, 315. [\[CrossRef\]](#) [\[PubMed\]](#)
132. Dopfer, E.P.; Hartl, F.A.; Oberg, H.-H.; Siegers, G.M.; Yousefi, O.S.; Kock, S.; Fiala, G.J.; Garcillán, B.; Sandstrom, A.; Alarcón, B.; et al. The CD3 conformational change in the $\gamma\delta$ T Cell Receptor is not triggered by antigens but can be enforced to enhance tumor killing. *CellReports* **2014**, 1–12. [\[CrossRef\]](#) [\[PubMed\]](#)
133. Janssen, O.; Wesselborg, S.; Heckl-Ostreicher, B.; Pechhold, K.; Bender, A.; Schondelmaier, S.; Moldenhauer, G.; Kabelitz, D. T cell receptor/CD3-signaling induces death by apoptosis in human T cell receptor gamma delta + T cells. *J. Immunol.* **1991**, *146*, 35–39. [\[PubMed\]](#)

134. Oberg, H.H.; Peipp, M.; Kellner, C.; Sebens, S.; Krause, S.; Petrick, D.; Adam-Klages, S.; Rocken, C.; Becker, T.; Vogel, I.; et al. Novel Bispecific Antibodies Increase T-Cell Cytotoxicity against Pancreatic Cancer Cells. *Cancer Res.* **2014**, *74*, 1349–1360. [\[CrossRef\]](#)
135. Blank, C.U.; Haanen, J.B.; Ribas, A.; Schumacher, T.N. CANCER IMMUNOLOGY. The “cancer immunogram”. *Science* **2016**, *352*, 658–660. [\[CrossRef\]](#)
136. Oberg, H.-H.; Kellner, C.; Peipp, M.; Sebens, S.; Adam-Klages, S.; Gramatzki, M.; Kabelitz, D.; Wesch, D. Monitoring Circulating $\gamma\delta$ T Cells in Cancer Patients to Optimize $\gamma\delta$ T Cell-Based Immunotherapy. *Front. Immunol.* **2014**, *5*, 643. [\[CrossRef\]](#)
137. Cristescu, R.; Mogg, R.; Ayers, M.; Albright, A.; Murphy, E.; Yearley, J.; Sher, X.; Liu, X.Q.; Lu, H.; Nebozhyn, M.; et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. *Science* **2018**, *362*, eaar3593. [\[CrossRef\]](#)
138. Cesano, A.; Warren, S. Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic. *Biomedicines* **2018**, *6*, 14. [\[CrossRef\]](#)
139. Topp, M.S.; Gökbuget, N.; Stein, A.S.; Zugmaier, G.; O’Brien, S.; Bargou, R.C.; Dombret, H.; Fielding, A.K.; Heffner, L.; Larson, R.A.; et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. *Lancet Oncol.* **2015**, *16*, 57–66.
140. Kantarjian, H.; Stein, A.; Gökbuget, N.; Fielding, A.K.; Schuh, A.C.; Ribera, J.-M.; Wei, A.; Dombret, H.; Foà, R.; Bassan, R.; et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. *N. Engl. J. Med.* **2017**, *376*, 836–847. [\[CrossRef\]](#)
141. Duell, J.; Dittrich, M.; Bedke, T.; Mueller, T.; Eisele, F.; Rosenwald, A.; Rasche, L.; Hartmann, E.; Dandekar, T.; Einsele, H.; et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. *Leukemia* **2017**, *31*, 2181–2190. [\[CrossRef\]](#) [\[PubMed\]](#)
142. Day, C.-P.; Merlino, G.; Van Dyke, T. Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges. *CELL* **2015**, *163*, 39–53. [\[CrossRef\]](#) [\[PubMed\]](#)
143. Holderness, J.; Hedges, J.F.; Ramstead, A.; Jutila, M.A. Comparative Biology of $\gamma\delta$ T Cell Function in Humans, Mice, and Domestic Animals. *Annu. Rev. Anim. Biosci.* **2013**, *1*, 99–124. [\[CrossRef\]](#) [\[PubMed\]](#)
144. Hahn, A.M.; Winkler, T.H. Resolving the mystery—How TCR transgenic mouse models shed light on the elusive case of gamma delta T cells. *J. Leukoc. Biol.* **2020**, *154*, 5821–16. [\[CrossRef\]](#) [\[PubMed\]](#)
145. Shultz, L.D.; Brehm, M.A.; Garcia-Martinez, J.V.; Greiner, D.L. Humanized mice for immune system investigation: Progress, promise and challenges. *Nat. Rev. Immunol.* **2012**, *1*–13. [\[CrossRef\]](#) [\[PubMed\]](#)
146. Man, F.; Lim, L.; Volpe, A.; Gabizon, A.; Shmeeda, H.; Draper, B.; Parente-Pereira, A.C.; Maher, J.; Blower, P.J.; Fruhwirth, G.O.; et al. In Vivo PET Tracking of ^{89}Zr -Labeled $\text{V}\gamma 9\text{V}\delta 2$ T Cells to Mouse Xenograft Breast Tumors Activated with Liposomal Alendronate. *Mol. Ther.* **2019**, *27*, 219–229. [\[CrossRef\]](#)
147. Kabelitz, D.; Wesch, D.; Pitters, E.; Zöller, M. Characterization of Tumor Reactivity of Human $\text{V}\gamma 9\text{V}\delta 2$ $\gamma\delta$ T Cells In Vitro and in SCID Mice In Vivo. *J. Immunol.* **2004**, *173*, 6767–6776. [\[CrossRef\]](#)
148. Chitadze, G.; Oberg, H.-H.; Wesch, D.; Kabelitz, D. The Ambiguous Role of $\gamma\delta$ T Lymphocytes in Antitumor Immunity. *Trends Immunol.* **2017**, *38*, 668–678. [\[CrossRef\]](#)
149. Jarry, U.; Chauvin, C.; Joalland, N.; Léger, A.; Minault, S.; Robard, M.; Bonneville, M.; Oliver, L.; Vallette, F.M.; Vié, H.; et al. Stereotaxic administrations of allogeneic human $\text{V}\gamma 9\text{V}\delta 2$ T cells efficiently control the development of human glioblastoma brain tumors. *Oncoimmunology* **2016**, *5*, 1–10. [\[CrossRef\]](#)
150. Mao, T.; Miao, C.; Liao, Y.; Chen, Y.; Yeh, C.; Liu, C. Ex Vivo Expanded Human $\text{V}\gamma 9\text{V}\delta 2$ T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth. *Int. J. Mol. Sci.* **2019**, *20*, 1139. [\[CrossRef\]](#)
151. Santolaria, T.; Robard, M.; Léger, A.; Catros, V.; Bonneville, M.; Scotet, E. Repeated Systemic Administrations of Both Aminobisphosphonates and Human $\text{V}\gamma 9\text{V}\delta 2$ T Cells Efficiently Control Tumor Development In Vivo. *J. Immunol.* **2013**, *191*, 1993–2000. [\[CrossRef\]](#) [\[PubMed\]](#)
152. Zheng, B.J.; Chan, K.W.; Im, S.; Chua, D.; Sham, J.S.; Tin, P.C.; He, Z.M.; Ng, M.H. Anti-tumor effects of human peripheral gammadelta T cells in a mouse tumor model. *Int. J. Cancer* **2001**, *92*, 421–425. [\[CrossRef\]](#) [\[PubMed\]](#)
153. Di Carlo, E.; Bocca, P.; Emionite, L.; Cilli, M.; Cipollone, G.; Morandi, F.; Raffaghello, L.; Pistoia, V.; Prigione, I. Mechanisms of the Antitumor Activity of Human $\text{V}\gamma 9\text{V}\delta 2$ T Cells in Combination With Zoledronic Acid in a Preclinical Model of Neuroblastoma. *Mol. Ther.* **2013**, *21*, 1034–1043. [\[CrossRef\]](#) [\[PubMed\]](#)

154. Hodgins, N.O.; Al-Jamal, W.T.; Wang, J.T.W.; Klippstein, R.; Costa, P.M.; Sosabowski, J.K.; Marshall, J.F.; Maher, J.; Al-Jamal, K.T. Investigating in vitro and in vivo $\alpha\text{v}\beta 6$ integrin receptor-targeting liposomal alendronate for combinatory $\gamma\delta$ T cell immunotherapy. *J. Control. Release* **2017**, *256*, 141–152. [\[CrossRef\]](#)
155. Parente-Pereira, A.C.; Shmeeda, H.; Whilding, L.M.; Zambirinis, C.P.; Foster, J.; van der Stegen, S.J.C.; Beatson, R.; Zabinski, T.; Brewig, N.; Sosabowski, J.K.; et al. Adoptive Immunotherapy of Epithelial Ovarian Cancer with V γ 9V δ 2 T Cells, Potentiated by Liposomal Alendronic Acid. *J. Immunol.* **2014**, *193*, 5557–5566. [\[CrossRef\]](#)
156. Gertner-Dardenne, J.; Castellano, R.; Mamessier, E.; Garbit, S.; Kochbati, E.; Etienne, A.; Charbonnier, A.; Collette, Y.; Vey, N.; Olive, D. Human V γ 9V δ 2 T Cells Specifically Recognize and Kill Acute Myeloid Leukemic Blasts. *J. Immunol.* **2012**, *188*, 4701–4708. [\[CrossRef\]](#)
157. Malkovska, V.; Cigel, F.K.; Armstrong, N.; Storer, B.E.; Hong, R. Antilymphoma activity of human gamma delta T-cells in mice with severe combined immune deficiency. *Cancer Res.* **1992**, *52*, 5610–5616.
158. Xiang, Z.; Liu, Y.; Zheng, J.; Liu, M.; Lv, A.; Gao, Y.; Hu, H.; Lam, K.-T.; Chan, G.C.-F.; Yang, Y.; et al. Targeted Activation of Human V γ 9V δ 2 T Cells Controls Epstein-Barr Virus-Induced B Cell Lymphoproliferative Disease. *Cancer Cell* **2014**, *26*, 565–576. [\[CrossRef\]](#)
159. Zumwalde, N.A.; Sharma, A.; Xu, X.; Ma, S.; Schneider, C.L.; Romero-Masters, J.C.; Hudson, A.W.; Gendron-Fitzpatrick, A.; Kenney, S.C.; Gumperz, J.E. Adoptively transferred V γ 9V δ 2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model. *J. Clin. Invest. Insight* **2017**, *2*, 3202–3215. [\[CrossRef\]](#)
160. Pechhold, K.; Wesch, D.; Schondelmaier, S.; Kabelitz, D. Primary activation of V γ 9-expressing gamma delta T cells by Mycobacterium tuberculosis. Requirement for Th1-type CD4 T cell help and inhibition by IL-10. *J. Immunol.* **1994**, *152*, 4984–4992.
161. Chen, J.; Niu, H.; He, W.; Ba, D. Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes. *Int. Arch. Allergy Immunol.* **2001**, *125*, 256–263. [\[CrossRef\]](#)
162. D'Asaro, M.; La Mendola, C.; Di Liberto, D.; Orlando, V.; Todaro, M.; Spina, M.; Guggino, G.; Meraviglia, S.; Caccamo, N.; Messina, A.; et al. V γ 9V δ 2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells. *J. Immunol.* **2010**, *184*, 3260–3268. [\[CrossRef\]](#)
163. Beck, B.H.; Kim, H.-G.; Kim, H.; Samuel, S.; Liu, Z.; Shrestha, R.; Haines, H.; Zinn, K.; Lopez, R.D. Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. *Breast Cancer Res. Treat.* **2010**, *122*, 135–144. [\[CrossRef\]](#) [\[PubMed\]](#)
164. Dokouhaki, P.; Han, M.; Joe, B.; Li, M.; Johnston, M.R.; Tsao, M.-S.; Zhang, L. Adoptive immunotherapy of cancer using ex vivo expanded human $\gamma\delta$ T cells: A new approach. *Cancer Lett.* **2010**, *297*, 126–136. [\[CrossRef\]](#) [\[PubMed\]](#)
165. Lozupone, F.; Pende, D.; Burgio, V.L.; Castelli, C.; Spada, M.; Venditti, M.; Luciani, F.; Lugini, L.; Federici, C.; Ramoni, C.; et al. Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. *Cancer Res.* **2004**, *64*, 378–385. [\[CrossRef\]](#) [\[PubMed\]](#)
166. Oberg, H.-H.; Peters, C.; Kabelitz, D.; Wesch, D. Real-time cell analysis (RTCA) to measure killer cell activity against adherent tumor cells in vitro. *Meth. Enzym.* **2020**, *631*, 429–441.
167. García-Martínez, E.; Smith, M.; Buqué, A.; Aranda, F.; de la Peña, F.A.; Ivars, A.; Cánovas, M.S.; Conesa, M.A.V.; Fucikova, J.; Spisek, R.; et al. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. *Oncoimmunology* **2018**, *7*, 1–16.
168. Starick, L.; Riaño, F.; Karunakaran, M.M.; Kunzmann, V.; Li, J.; Kreiss, M.; Amslinger, S.; Scotet, E.; Olive, D.; De Libero, G.; et al. Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates V γ 9V δ 2 TCR clonotypes and interferes with phosphoantigen activation. *Eur. J. Immunol.* **2017**, *47*, 982–992. [\[CrossRef\]](#)
169. Crowther, M.D.; Dolton, G.; Legut, M.; Caillaud, M.E.; Lloyd, A.; Attaf, M.; Galloway, S.A.E.; Rius, C.; Farrell, C.P.; Szomolay, B.; et al. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. *Nat. Immunol.* **2020**, *21*, 178–185. [\[CrossRef\]](#)

